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ABSTRACT

T-cell Dysfunction by HCV Core Protein Involves PD-1/PD-L1 Signaling

by
Ellis King

In 1989 the hepatitis C virus was identified as a significant cause of posttransfusion hepatitis. Nearly two decades later there is still no vaccine,
inadequate treatment options, and limited understanding of how the virus
establishes chronicity in the majority of the people it infects. Recent reports
suggest that the interaction of a negative co-stimulatory pathway mediated by
PD-1 and PDL-1 is associated with persistent viral infection. The role, if any, that
PD-1/PDL-1 has in HCV infection is unknown. In this study we report that PD-1
is upregulated in T-cells from persons with chronic HCV infection when
compared to healthy donors. In addition, PD-1 and PDL-1 are upregulated on Tcells from healthy donors when exposed to extracellular HCV core protein (a
nucleocapsid protein that is immunosuppressive); upregulation of PD-1 is
mediated by core’s ability to bind to the complement receptor gC1q. We also
report that the observed T-cell function can be restored by blocking the PD1/PDL-1 interaction. Our results indicate that HCV core can upregulate an
important negative T-cell signaling pathway that is associated with viral
persistence. This upregulation of PD-1/PDL-1 represents a novel and perhaps
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shared mechanism that viral pathogens may use to subvert the human immune
response. It also represents a potential new treatment option for the millions of
people who suffer from chronic hepatitis C infection.
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CHAPTER 1

INTRODUCTION

A Brief History of Post-Transfusion Hepatitis

The possibility and need for large scale transfusion medicine came
together in the 1940s. Medical science had advanced sufficiently to provide the
possibility and World War II provided the need. So, began the establishment and
growth of blood banks, transfusion services, and other related laboratory support.
It was quickly realized that hepatitis could be transmitted via blood or blood
products when post-transfusion hepatitis (PTH) was first reported in the U.S. by
(Beeson 1943). However, the demand for blood continued to grow and by the
early 1970s there were over 5000 organizations involved in transfusion medicine
with over 12 million units of whole blood transfused per year (Domen 1995). The
increased demand brought increased disease transmission; an NIH study during
this time reported that the risk of PTH was 6.3% when a patient was transfused
with blood from a commercial donor and <0.6% for blood from a volunteer donor
(Walsh and others 1970).
In 1965 the first marker for PTH was identified and termed the Australian
antigen (Blumberg and others 1965). By 1970 the Australian antigen had been
re-named as the hepatitis B surface antigen (HbsAg) (Gocke and others 1969;
Gocke and others 1970) and in 1972 the FDA required all blood donations within
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the U.S. to be screened for HBsAg (Hoofnagle 1990). These efforts and the
FDA decision to disallow commercial donors (persons who donate blood for
money) lowered the PTH rate to 7.1% of the prior rate (Alter and others 1972).
The next major discovery was in 1973 (Feinstone and others 1973) when the
hepatitis A virus (HAV) was identified as an agent of acute hepatitis. However
within a few years, it was determined that HAV was not the cause of the nonHBV cases of PTH (Dienstag and others 1977; Stevens and others 1978). The
still unidentified agent of hepatitis was termed non-A, non-B hepatitis (NANBH)
and represented 90% of residual PTH cases in the 1970s and early 1980s.
It was not until 1988 that a new hepatitis virus was identified by Houghton
and associates at Chiron in collaboration with Bradley of the Hepatitis Branch of
the Centers for Disease Control (Ezzell 1988). Choo and others then used a
cDNA library generated from a patient with NANB hepatitis to screen the serum
of a patient with chronic NANBH. A complementary DNA clone was isolated that
was shown to encode an antigen associated specifically with NANBH infections
(Choo and others 1989). This positive clone and this new virus were associated
and named hepatitis C virus (HCV).

Hepatitis C Virus
Since 1998 the Centers for Disease Control and Prevention (CDC)
estimate that >40,000 new infections with hepatitis C virus (HCV) occur every
year making HCV infection the most common chronic bloodborne viral infection
in the United States. The third National Health and Nutrition Examination Survey
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(NHANES III) based on data collected from 1988-94, found that within the
civilian, non-institutionalized U.S. population 3.9 million American were infected
with 2.7 million chronically infected. If this prevalence rate of 1.8% is
extrapolated to today’s population of 300 million then >5 million Americans are
presently infected with nearly 3.5 million chronically infected. These estimates
are likely conservative due to the exclusion of incarcerated (infection rates
estimated to be 15-40%, CDC) and homeless persons, groups that generally
have a high prevalence of HCV infection. Presently, most HCV infected persons
are adults between the ages of 30-49 years old (Alter and others 1997; Alter
1997). Given that HCV infection can take years to become clinically significant,
most persons are probably infected in their early adulthood. Males are almost
twice as like to be infected compared to females.
As shown in Figure 1.1, the greatest present day risk of HCV infection
comes with injecting drug use. Of persons injecting drugs for at least 5 years,
60% to 80% are infected with HCV compared to an approximately 30% infected
with HIV.
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Figure 1.1 Sources of Infection for Persons with Hepatitis C. * Hemodialysis; health-care work;
perinatal. Source – CDC

Current screening and testing procedures for donated blood have reduced the
likelihood of contracting HCV from a transfusion to less than one per million units
transfused. These same procedures, plus virus inactivation procedures, have
allowed only one instance of infection from contaminated blood products since
the testing/screening procedures were put in place in the U.S. Although the risk
from sexual intercourse is low, sex is a common behavior in the general
population. So, while other types of exposure have a relatively greater risk (e.g.,
transfusion from an infected donor), they account for a relatively small proportion
of the population in whom these exposures have occurred. The remaining
groups at risk – health care worker exposure, vertical transmission from mother
to child, and persons undergoing hemodialysis account for approximately 5% of
new infections. Approximately 10% of infected persons have no recognized
source for their infection.
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Preventing and treating HCV is problematic. Currently no vaccine exists
and no likely candidates are in the near future. In the U.S., HCV genotypes 1a
and 1b are most prevalent (Hoofnagle 1997) and the most resistant to the
currently recommended therapy of pegylated interferon alpha and ribavirin
(Hoofnagle 2003). Peginterferon alpha and ribavirin will achieve a sustained
elimination of HCV infection for at least 6 months in 30% to 40% of patients who
complete their therapy. An additional 10% to 20% of patients do not complete
the therapy due to the side effects of the medication or have contraindications
(such as sever cirrhosis) that prohibit treatment. This combination treatment will
also induce a sustained virologic response (SVR) in 42-48% of persons infected
with genotype 1a or 1b, whereas the same treatment will induce a SVR in 7688% of persons infected with genotypes 2 or 3 (Fried and others 2002).
Additional contra indicators also exist. IFN alpha is associated with depression
and ribavirin can cause neutropenia and can have a teratogenic effect. Current
antiviral therapy is not approved for patients below the age of 18.
The study of HCV is made difficult by two key factors. HCV will only
reliably infect humans and chimpanzees, thus limiting animal models.
Additionally, in vitro replication is very poor (although some replicon systems
have been made to work in hepatocytes.) Because newly infected persons are
usually asymptomatic and, therefore, almost never clinically recognized as
infected, it has also been difficult to determine the initial immune responses that
correlate with viral clearance. To further compound the issue, it appears that the
six major genotypes described (Simmonds and others 1993a) may have different
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disease patterns and different responses to treatment (Hoofnagle and di
Bisceglie 1997). Finally, in spite of strong evidence linking HCV infection to
numerous conditions involving the immune system, diseases associated with
immune dysfunction occur frequently in persons without HCV infection, and so it
has been difficult to confirm strong associations between HCV and a given
disease.
Hepatitis C is a 9.5-kb positive strand RNA virus of the Flaviviridae family.
The genome consists of ~9500 nucleotides encoding a single polypeptide of
~3000 amino acids that is cleaved into structural and non-structural proteins. It
encodes three structural proteins (core, E1, and E2) and at least six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B). HCV is
classified into 6 distinct but related genotypes; HCV is further divided into over 50
subtypes based on sequence variation in the core and E1 genes and also shows
significant geographical variation (Simmonds and others 1993b). Persons with
long-term infections also tend to have greater levels of genetic diversity within
their genotypes (quasispecies) (Honda and others 1994; Farci and others 1997),
most likely due to the poor fidelity of the HCV RNA polymerase. The phenomena
of high levels of quasispecies is also associated with poor clinical prognosis
(Kanazawa and others 1994), that may be linked to the poor CTL response in
chronically infected persons.
A remarkable feature of HCV is its ability to evade the host immune
response, resulting in chronic infection for over 80% of persons exposed. The
high incidence of persistent infection with HCV suggests that this virus has
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evolved one or more mechanisms to evade and possibly suppress the host
immune response. Chronic HCV infections are associated with liver cirrhosis
and hepatocellular carcinoma and have become a leading indicator for liver
transplant in the U.S. (Hoofnagle 1997). Cirrhosis of the liver develops in 10%
to 20% of persons with chronic hepatitis C over a period of 2-30 years, and
hepatocellular carcinoma (liver cancer) in 1% to 5% of those with cirrhosis. In
addition to cirrhosis and carcinoma, persons infected with HCV are also at a
significant risk of developing autoimmune diseases such as glomerulonephritis
and mixed cryoglubulinemia (Agnello and De Rosa 2004). Hepatitis C disease
progression varies greatly from person to person making it not only difficult to
predict who will develop chronic disease but also which of the chronically infected
will go on to develop significant sequellae. One thing that is known is the impact
of alcohol use in infected persons. Chronically infected persons who abuse
alcohol have a greater risk of developing cirrhosis and also be refractory to the
effect of any anti-viral medication.
While the precise mechanisms for how the disruption of the host immune
response by HCV can result in various immune disorders have yet to be defined;
however it is apparent that HCV modulates host immunity on several different
levels (Moorman and others 2001b). Over the past decade, there have been
numerous studies examining different facets of HCV-associated immune
dysfunction that have included B-cell, T-cell, NK cell, and dendritic cell
dysregulation (King and others 2007). The significance of such
immunomodulatory potential appears to be twofold: evasion of the host immune
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response leading to viral chronicity, and the potential for development of
lymphoproliferative disorders.
It is noteworthy that HCV clearly infects multiple extrahepatic cell types,
including peripheral blood mononuclear cells, and this is observed both in vivo
and in vitro (Shimizu and others 1992; Shimizu and others 1997; Lerat and
others 1998; Radkowski and others 2000; Radkowski and others 2002; Nowicki
and others 2005). It is therefore possible that the immune dysfunction observed
in HCV is a function of its ability to infect such cells, although the frequency of
this infection appears low (Bronowicki and others 1998). HCV sequences
observed in different cellular compartments and in particular peripheral blood
mononuclear cells may vary, suggesting viral tropism for specific cells that may
be in part affected by the HCV diversity that occurs as quasispecies develop
(Lerat and others 1998). The role of a given genotype in targeting hematopoetic
cells remains controversial (Kao and others 1997; Lerat and others 1998).

Dysregulation of B Cell Function Mediated by HCV
Because the association between chronic HCV infection and both mixed
cryoglobulinemia and B-cell lymphoma was first recognized, there have been an
increasing number of studies examining B cell dysfunction in the context of
chronic HCV infection. While it has clearly been shown that clonal populations of
B lymphocytes are disproportionately present in increased numbers in patients
with chronic HCV infection, there are also numerous data detailing specific
mechanisms behind B cell clonality. Moreover, such mechanisms offer insight
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into the presence of immune dysfunction in patients with chronic HCV infection.
Most notably, B cells have become a target of drug development for the
treatment of certain HCV-associated immune diseases (Kazkaz and Isenberg
2004).
(Franzin and others 1995), were the first to report the presence of clonal B
cell expansion in the peripheral blood of 38 HCV-infected patients. Subset
analyses in their study revealed the presence of clonal immunoglobulin gene
rearrangements in 100% of HCV-positive patients with type II mixed
cryoglobulinemia (MC) as opposed to only 24% in HCV-positive patients without
mixed cryoglobulinemia. The reversibility of B cell clonality in chronic HCV
infection was similarly assessed in a cohort of 20 patients with HCV-associated
MC undergoing interferon alpha therapy (Mazzaro and others 1996). While 80%
of these patients (all of whom were noted to have clonal populations of B cells)
achieved complete or partial clinical responses, 15% reverted to polyclonal B cell
populations following therapy. Recent studies also suggest upregulation of Blymphocyte stimulator (BLyS) in the setting of MC (Fabris and others 2006; Sene
and others 2006), further supporting a significant relationship between clonal
expansion of B lymphocytes and HCV-associated mixed cryoglobulinemia.
(Zignego and others 2000), found an increased frequency of bcl-2 gene
rearrangement (Mazzaro and others 1996; Nowicki and others 2005) in a
prospective study of individuals with HCV and mixed cryoglobulinemia (Antonelli
and others 2002), while (Toubi and others 2004), observed enhanced B cell
apoptosis in B cells from chronically infected HCV patients. There was relative
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resistance to apoptosis seen in the CD95/Fas+ B cell subpopulation, suggesting
a potential role for this subpopulation in B cell proliferative disorders.
As the propensity of HCV to induce lymphoproliferation in patients with
HCV-associated mixed cryoglobulinemia has been further elucidated, there has
been some effort to define the underlying mechanisms. (Machida and others
2005), reported that an HCV E2-CD81 interaction modulates host B cell
responses by enhancing activation-induced cytidine deaminase (AID) and
hypermutating V(H) immunoglobulin genes in B cells, suggesting a mechanism
for HCV-associated B cell lymphoproliferative disorders. HCV E2 was also
shown to activate the JNK pathway leading to preferential proliferation of CD27+
B cells (Rosa and others 2005).
The effect of HCV core protein on molecular profiling in human Blymphocytes was recently examined by (Wu and others 2006), who found
dramatic evidence for inhibition of B lymphocyte apoptosis by HCV core in
several steps of the apoptotic cascade. The investigators expressed HCV core in
an adenoviral vector in a healthy population of human B lymphocytes and
observed down regulation of MHC class II molecules and caspase-1 and -4,
which are proapoptotic proteins. Up regulation of nuclear factor kappa light
peptide inhibitor gene and TATA box protein, both of which are associated with B
cell lymphoma, was also observed. These findings underscore the potential of
HCV to disrupt antigen presentation and apoptosis and may indicate yet another
mechanism for HCV-related autoimmunity and lymphoproliferation.
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Oncogenes have also been a focus of investigation in patients with MC.
In a prospective study of 37 patients with HCV-associated mixed
cryoglobulinemia, (Zignego and others 2000), found that 75.7% had bcl-2
rearrangements in peripheral blood mononuclear cells, as opposed to 37.6% of
patients with chronic HCV infection without mixed cryoglobulinemia (Antonelli
and others 2002). (Galli-Stampino and others 2003), further expanded on the
relationship between oncogenesis and clonal B cell expansion in patients with
HCV-associated mixed cryoglobulinemia by demonstrating the presence of
restricted V(H)I gene sequences in peripheral blood, hepatic, and lymph node B
lymphocytes in three of four patients (Galli-Stampino and others 2003). These
gene sequences are usually associated with B-cell non-Hodgkin’s lymphoma
(NHL) and their presence in patients with chronic HCV patients may indicate a
mechanism of developing NHL through non-malignant, clonally expanded B-cell
populations.

Type I Interferon Dysregulation
Interferon-alpha stimulation is a critical and non-specific response to viral
infection. Its two main effects are induction of an anti-viral state in infected cells
and interferon receptor ligation that results in activation of Janus kinase (Jak) and
signal transducer and activator of transcription (STAT). Jak/STAT signaling in
turn activates numerous interferon-response genes including 2’-5’ oligoadenylate
synthetase (OAS), Mx proteins and the double-stranded RNA dependent protein
kinase (PKR) (Katze 2002). PKR is induced by double stranded viral RNA and,
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in-turn, phosphorylates eukaryotic initiation factor 2 (elF-2), resulting in inhibition
of cellular protein syntheses and viral replication. Two HCV proteins, the
envelope glycoprotein E2 and the nonstructural protein NS5A, have been
reported as potential inhibitors of the IFN response (Taylor 2000; Pflugheber and
others 2002).
Phosphorylated interferon regulatory factor 3 (pIRF-3) is the key
transcription regulatory factor for type I interferon (Foy and others 2003). Type I
interferon, in turn, upregulates expression of double-stranded RNA-dependent
protein kinase (PKR) that is a negative regulator of cell growth. Recently, the
HCV protein NS3/4A (a serine protease) was shown to interrupt the IFN signaling
pathway. Thus, in the presence of NS3/4A, IRF-3 is never phosphorylated and
IFN production is not induced (Foy and others 2003). The importance of IRF-3
was also demonstrated with mutations resulting in dominant negative or
constitutively active IRF-3 leading to enhanced or restrained HCV replication,
respectively.

Dysregulation of the NK Response
Natural killer (NK) cells play a critical role in innate immunity. NK cells
mediate lysis of target cells by releasing cytotoxic granules that contain perforin
and granzymes or by binding apoptosis inducing receptors on the target cells.
NK cells also secrete numerous cytokines including IFN-gamma and TNF-alpha
during inflammation (Poccia and others 2001). Recent reports have implicated
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the HCV E2 protein in suppression of NK activity (Crotta and others 2002; Tseng
and Klimpel 2002).
The HCV E2 protein binds CD81, which is expressed on the surface of
host cells. When NK cells are exposed to immobilized E2 or anti-CD81 (in vitro),
their function is impaired. The impairment ranges from suppression of
cytotoxicity and IL-2 induced proliferation to suppression of IL-2, IL-12, and IL-15
mediated induction of IFN-gamma (Crotta and others 2002; Tseng and Klimpel
2002). Additionally, ligation of CD81 by E2 inhibits CD16-mediated activation of
extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase
(MAPK) in NK cells (Crotta and others 2002). These mechanisms, if employed
by HCV, could facilitate HCV persistence. However, this possibility needs further
research as NK cells do not play a role in all viral infections.

Dysregulation of Dendritic Cells by HCV Envelope Glycoproteins
One possible cause of an impaired CD8+ response to HCV infection may
be abnormal dendritic cell (DC) function preventing appropriate antigen
processing and presentation. Interestingly, HCV E1 and E2 glycoproteins
interact with DC-specific intercellular adhesion molecule 3 (ICAM-3),
sequestering nonintegrin (DC-SIGN) and its receptor, DC-SIGNR, in immature
DCs (Lozach and others 2003; Pohlmann and others 2003). The role of HCV
interactions with DC remains controversial. Numerous studies demonstrate
abnormal DC activity in chronic HCV patients, yet recent studies by (Longman
and others 2005), report the converse.
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In addition to envelope proteins, HCV core has also been implicated in
inhibiting DC and macrophage function (Sarobe and others 2003). Addition of
extracellular core or expression of core/E1 in mice by recombinant adenovirus
demonstrated an effect on DC maturation and T cell responses upon allogenic
stimulation. A molecular mechanism(s) has not fully elucidated to explain this
inhibition.

Dysregulation of T Cell Function Mediated by HCV Core Protein
Evidence suggests that the 21kD HCV core protein, the first to be
synthesized during infection, contains multiple functions that have numerous
downstream effects on immune related cellular responses. This
immunomodulatory effect has been demonstrated by the suppression of anti-viral
CTL activity (Large and others 1999b) and diminished T cell responses to HBV
envelope proteins in mice immunized with HCV-core/HBV chimeric constructs
(Geissler and others 1998). HCV core has also been found circulating in the
bloodstream of infected patients (Maillard and others 2001) suggesting that the
effects of core may extend beyond the specific cells that are infected with HCV.
This is important because in relative numbers, HCV infects few peripheral blood
mononuclear cells (PBMCs) (e.g. lymphocytes). Furthermore, extracellular HCV
core has been shown to inhibit the T lymphocyte responses that are crucial for
viral clearance (Kittlesen and others 2000; Yao and others 2001a), thus implying
a role for core in establishing chronicity. It is well known that, in general, an early
and sustained virus-specific T-cell response is critical for viral clearance (Missale
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and others 1996; Cooper and others 1999; Gerlach and others 1999; Gruner and
others 2000; Takaki and others 2000; Thimme and others 2001). However, in
patients who are chronically infected with HCV, the frequency of virus specific Tcells is relatively low. Furthermore, the effector functions of HCV specific
CD4+/CD8+ cells as well as the production of Th1-type cytokines (e.g. IL-2 and
interferon gamma) are severely decreased (Rehermann and others 1996; Chang
and others 1997; Lechmann and others 1999; Wedemeyer and others 2002;
Sugimoto and others 2003). It is clear that HCV will establish a chronic infection
in most persons who are infected. The available data strongly support the
thought that HCV, through some action(s), suppresses the human immune
system, thus establishing chronicity. The available data also strongly suggest
that the HCV core protein has a significant, yet not fully understood role, in the
immune suppression.
Studies have implicated that gC1qR (the glycoprotein portion of the C1q
cellular receptor) is the cellular target of core protein (Kittlesen and others 2000).
The natural ligand for gC1qR is C1q. C1q is an integral part of the C1q complex
that is well established as the first component in the classical pathway of
complement activation, thus playing a critical role in the early defense against
foreign antigens (Ghebrehiwet and others 2001). The 33kD gC1qR and the
60kD cCqR bind the globular “head” and collagen-like “stalk” domains of C1q,
respectively, and form a hetrodimer that is expressed in most cell types, including
T cells (Ghebrehiwet and others 2001). Interestingly, treatment of PBMCs with
extracellular HCV core leads to suppression of T-cell proliferation in a manner
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similar to that observed when T-cells are exposed to C1q (Chen and others
1994; Kittlesen and others 2000). This suppressive effect can be abrogated by
the addition of anti-gC1qR suggesting that core is indeed mediating suppression
through gC1qR. Therefore, the interaction between HCV core and gC1qR may
provide the virus with a means to affect the human host immune response.
gC1qR has also been reported to interact with several other viral and
bacterial proteins potentially providing other micro-organisms with a “shared”
mechanism of immune evasion (Luo and others 1994; Bruni and Roizman 1996;
Wang and others 1997; Matthews and Russell 1998; Braun and others 2000;
Nguyen and others 2000). These data suggest that numerous human pathogens
exploit a similar strategy to subvert the host immune response. The underlying
mechanisms for the role of gC1qR in the interference of the immune system have
yet to be elucidated with regards to HCV infection as well as the other pathogens
that may use this pathway. It is, however, clear that the ability of HCV core to
alter the immune response is not as simple as it binding to gC1qR. In vitro
studies show that HCV core from genotype 1a will dampen the host immune
response (Yao and others 2006b), while other in vivo studies using HCV core
from genotype 1b conducted in transgenic mice report no such effect (Liu and
others 2002). This suggests that the immunosuppressive effects may be
genotype specific, and, indeed, this has been reported (Sugimoto and others
2005). Another in vitro study conducted in HepG2 cells reported that HCV core
genotype 1a will significantly suppress nuclear factor kappa-B (NF-kB) when
compared to genotype 1b (Ray and others 2002). NF-kB is a well-known
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transcription factor that is important in many cellular immune responses, as many
of its target genes; such as interferon beta, TNF alpha, IL-2, IL-6, and IL-8 are
immunologically relevant (Pellegrini and Schindler 1993). Yet, patients who are
infected with HCV genotype 1b still become chronically infected, further
suggesting host factor(s) impact whether a newly infected person clears the virus
or becomes chronically infected. This is supported by studies conducted in
chimpanzees that showed the level of innate expression of gC1qR will affect
core’s ability to suppress the immune system. Chimpanzees that had lower
levels of gC1qR expression were more likely to resolve the HCV virus challenge
versus those chimpanzees with higher levels of innate gC1qR expression (Yao
and others 2006a).
To date and with regard to HCV core-gC1qR binding and any subsequent
immune suppression, most of the data produced have come from work in
lymphocytes; lymphocytes obtained from either cell lines, such as Jurkats, or
primary lymphocytes isolated from human volunteers. One notable exception
was a set of experiments conducted in normal human lung fibroblasts (NHLF)
cell line. The impetus for this study was reported links of HCV infection to
declines in pulmonary function in patients with underlying pulmonary diseases
such as asthma and chronic obstructive pulmonary disease (Kanazawa and
others 2003; Kanazawa and Yoshikawa 2004). The study investigators focused
on IL-8 stimulation given its known role in mediating inflammatory pulmonary
processes and general pulmonary pathology (Kaplanski and others 1997; Polyak
and others 2001; Mukaida 2003). They found that when HCV core is added to
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cultures of NHLFs in an extracellular manner, IL-8 mRNA and protein are
stimulated in a dose and time dependent manner (Moorman and others 2005b).
They also reported that this up-regulation could be blocked by the addition of
anti-gC1qR that blocks the core binding site on gC1qR. While more studies need
to be conducted in this area, this study offers an intriguing glimpse toward other
(non-PBMC) possible ramifications of interactions between core and gC1qR.
The early lymphocyte work investigating the consequences of core-gC1qR
binding employed transfection methods in order to introduce core to the cell and
focused on core’s ability to induce or up-regulate apoptosis of T-cells. These
studies found that transient expression of core appeared to up-regulate apoptosis
mediated by interaction with members of the tumor necrosis family of receptors
(TNFR) (Hahn and others 2000; Zhu and others 2001; Moorman and others
2003). It was found that expression of core sensitized Jurkat cells to FasL
induced apoptosis (Hahn and others 2000) mediated by the cytoplasmic domain
of Fas. Additional studies also indicate that core can induce ligand independent
apoptosis of Jurkats by activating caspase 3 and 8. This same study also
reported that intracellular expression of core can also induce Fas multimerization
at the cellular level as a means of activating the apoptotic pathway (Moorman
and others 2003). While the evidence indicating that expression of HCV core will
induce apoptosis in a T-cell cell line is strong, it is worth remembering that, as
noted earlier, HCV infects a relatively low number of PBMCs. Yet, in spite of
HCV trophism for lymphocytes, the immune system can still produce HCV
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specific T cells and HCV antibody, neither of which have significant efficacy given
the high rate of chronicity.
While inducement of apoptosis in T-cells may have a role in HCV
establishing a chronic infection, it is likely that T-cell inhibition or suppression
plays a larger role. The search for a molecular basis for HCV core’s ability to
suppress the immune system has identified several possibilities, all mediated by
core’s ability to bind to gC1qR. Core was first found to inhibit proliferation in
activated T-cells by blocking the phosphorylation of extracellular signal-regulated
kinase (ERK) and mitogen-activated ERK kinase (MEK) (Yao and others 2001a)
in activated T-cells. HCV core-induced impairment of ERK/MEK mitogenactivated protein kinase resulted in the inhibition of IL-2 and IL-2R gene
transcription that led to the inhibition of IL-2 production and high-affinity IL-2R
alpha expression. Importantly, the ability of anti-gC1qR Ab treatment to reverse
HCV core-induced inhibition of ERK/MEK phosphorylation reveals that the
interaction between HCV core and gC1qR is linked to the interference of
ERK/MEK mitogen-activated protein kinase activation. HCV core has also been
shown to inhibit cell cycle progression from G1 to S phase by stabilizing p27Kip1,
which is a negative regulator of Cdk4/cyclin D and Cdk2/cyclin E (Yao and others
2003) complexes. These cyclin dependent kinases (Cdk) and their cyclin
partners serve to phosphorylate proteins that push cells from G1 to S phase.
Therefore, stabilization of proteins that inhibit these Cdk-cyclin complexes will in
turn lead to inhibition of cell cycle progression.
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Further studies have reported additional instances of core interfering with
cellular signaling. As previously mentioned, core will bind to the complement
receptor gC1qR whose natural ligand is C1q and that C1q also delivers inhibitory
signals to T-cells. Recent studies have shown that the affinity of core for gC1qR
is greater than that of C1q, and core appears to deliver stronger inhibitory signals
than does C1q (Yao and others 2004). These same studies also reported that
CD8+ T-cells are more susceptible to core meditated inhibition than CD4+ cells
most likely due to CD8+ cells having higher expression of gC1qR. Based on
previously reported data that indicated core had an inhibitory effect on ERK/MEK
signaling in T-cells (Yao and others 2001a) the investigators searched for other
inhibitory effects on signaling. They focused on early signaling in the early
stages of T-cell activation and found that core treated T-cells show a decrease in
the expression of Src kinases, Lck, and ZAP-70 that may impede cell cycle
progression (Yao and others 2004). Some of the latest data regarding signaling
inhibition was conducted using recombinant core from patients who had a
chronic infection versus patients who had spontaneously resolved their infection.
It was found that core from the chronic patients had a greater inhibitory effect
possibly mediated by diminishing the phosphorylation of STAT1/3 that, in turn, up
regulates the expression of SOCS1/3 (Yao and others 2006b), which are
negative regulators of T-cell proliferation. This finding is strengthened when
siRNAs, designed against SOCS1/3, abrogated the core mediated T-cell
inhibition.
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Programmed Cell Death 1 (PD-1).
In the early 1990s Honjo and colleagues began to search for gene
products that contributed to apoptotic cell death that was dependent on de novo
synthesis of RNA and protein e.g., the classical type programmed cell death.
They began their work in four cells lines of consisting of T-cells, B-cells, and a
lymphoid progenitor line. In 1992 they reported that in two of the four cell lines
de novo synthesis of RNA was necessary for apoptosis to occur. Further work
determined that a novel member of the immunoglobulin gene superfamily,
termed program cell death 1 (PD-1), was linked to the observed apoptosis (Ishida
and others 1992).
By 2002 it had been reported that, in vivo, PD-1 was expressed
predominately on activated T-cells (Iwai and others 2002). Further studies
indicated that cross-linking of PD-1 with its ligand would induce phosphorylation
of its immunoreceptor tyrosine-based switch motif that would then recruit SHP-2
with its subsequent negative regulatory signal (Okazaki and others 2001). The
ligands were then identified as PD-L1 (B7-H1) and PD-L2 (B7-DC) (Dong and
others 1999; Freeman and others 2000; Latchman and others 2001; Tseng and
others 2001) with PD-L1 shown to be expressed in numerous nonlymphoid tissue
(Dong and others 1999; Freeman and others 2000). The receptor-ligand
distribution pattern, PD-1 expressed in activated T-cells and PD-L1 expressed in
peripheral tissue, led to the hypothesis that PD-1/PD-L1 interaction might occur
at the effector phase of the immune response when activated T-cells migrate to
sites of inflammation or infection. Beginning with known liver involvement in the
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immune response, a set of experiments was designed around liver
nonparenchymal cells (LNPCs). It was found that PD-L1 was constitutively
expressed on LNPCs and that this expression was essential to inhibit
proliferation of activated T-cells in the liver (Iwai and others 2003), suggesting
that the PD-1/PD-L1 interaction may play important roles in the negative
regulation of immune responses in the liver.
The pathways that memory CD8+ T-cells take after an acute viral infection,
versus a chronic infection, are distinct (Wherry and others 2003; Wherry and
others 2004; Klenerman and Hill 2005). Memory CD8+ T-cells generated from an
acute viral infection are, in general, highly functional and make up an important
component of protective immunity. On the other hand, memory CD8 T-cells
generated from a chronic viral infection are often characterized by varying
degrees of functional impairment that is the most likely reason the virus is able to
establish a chronic infection. However, even in viral infections that eventually
become chronic, initial T effector cells are generated. Yet, they soon lose
function over the course of a chronic infection and become ‘exhausted’. This
exhaustion effect was first reported in mice with a chronic LCMV infection
(Gallimore and others 1998; Zajac and others 1998) but was quickly shown to be
a factor in humans with chronic viral infections; particularly those persons with
human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C
virus (HCV) (Letvin and Walker 2003; Pantaleo and Koup 2004; Rehermann and
Nascimbeni 2005).
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The next step taken was to determine gene expression in exhausted Tcells versus functional T-cells in the mouse LCMV model. PD-1 mRNA and
protein was found to be significantly up-regulated in the exhausted T-cells
(Barber and others 2006) when compared to the functional T-cells. Further
investigation by found that the LCMV strain that consistently causes an acute
infection in mice had only transient up-regulation of PD-1 mRNA and protein,
whereas the strain that consistently causes a chronic infection had higher and
sustained levels of PD-1 mRNA and protein. They then determined that by
blocking the PD-1/PD-L1 interaction they could restore function, e.g. the
exhausted T-cell where induced to clonally expand, to CD8+ cells even in the
absence of CD4+ cells.

Hypothesis
Based on the available data the following hypothesis is considered:
Persistence of HCV infection is mediated by the dysregulation of the PD-1
pathway in T-cells via HCV core-gC1qR interaction.
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CHAPTER 2

T cell Dysfunction by HCV Core Protein Involves PD-1/PDL-1 Signaling

Abstract

Recent reports show that a negative T cell co-stimulatory pathway mediated by
PD-1 and PDL-1 is associated with T cell exhaustion and persistent viral
infection. Persistent hepatitis C virus (HCV) infection in humans is also
characterized by impaired T lymphocyte function, but the role of the PD-1 and
PDL-1 pathway in HCV infection is unknown. Here we report that T cells isolated
from chronically infected HCV patients express significantly higher levels of PD-1
when compared to healthy donors. In addition, PD-1 and PDL-1 expression is
up-regulated on T cells from healthy donors exposed to HCV core, a
nucleocapsid protein that is immunosuppressive; up-regulation of PD-1 is
mediated through interaction of HCV core with the complement receptor, gC1qR.
Importantly, T cell functions that are dysregulated by HCV core, including T cell
activation, proliferation, and apoptosis, can be restored by blocking PD-1 or PDL1 engagement. Our results indicate that HCV core can up-regulate a key
negative T cell signaling pathway associated with viral persistence and highly
expressed on the T cells of persistently infected individuals. This up-regulation of
the PD-1 and PDL-1 pathway in humans represents a novel and perhaps
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common mechanism by which a virus usurps host machinery to facilitate
persistence.

Introduction

T cell dysfunction is a common feature of many persistent viral infections,
although the underlining mechanism(s) remains poorly understood. Hepatitis C
virus (HCV) infection provides an excellent model to study the mechanisms of
persistent viral infection as this virus is remarkable at evading host immune
surveillance, resulting in chronic infection in the majority of infected individuals
(Moorman and others 2001a). Chronic HCV infection is associated with liver
cirrhosis and hepatocellular carcinoma and has become a leading cause of liver
transplantation in the United States (Lauer and Walker 2001). Numerous studies
have reported that effective T cell responses are crucial for viral clearance, and
impaired viral specific CD4+ and CD8+ T cell functions are associated with
chronic HCV infection (Gerlach and others 1999; Gruner and others 2000;
Lechner and others 2000; Takaki and others 2000; Thimme and others 2001;
Wedemeyer and others 2002; Shoukry and others 2003). Other studies have
suggested the possibility of a more non-specific immune dysregulation in the
setting of HCV infection, perhaps supported by the high frequency of
autoimmune disease in individuals with chronic HCV infection (Yao and others
2001a; Yao and others 2001b; Lucas and others 2004; Graham and others 2005;
Par and others 2006). Despite extensive investigations into the mechanisms of
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virus-mediated T cell dysfunction, it still remains unclear why a small percentage
of HCV patients exhibit effective T cell responses and clear the virus following
acute infection, while the vast majority fail to do so and progress to chronic
infection.
It is likely that a gene product(s) encoded by HCV directly affects T cell
functions that are crucial for limiting virus replication, and thus facilitates
persistent infection. Several HCV-derived proteins, including the nucleocapsid
core protein, may play a role in the impairment of host immunity either directly or
through interaction with host molecules (Ray and Ray 2001; Eisen-Vandervelde
and others 2004). It has been previously demonstrated that HCV core protein is
necessary and sufficient to suppress host immune responses in a murine model
(Large and others 1999a). The molecular mechanism of HCV core-mediated
immunomodulation was subsequently determined by identifying a host-binding
partner, C1q complement receptor-gC1qR, on human T lymphocytes (Kittlesen
and others 2000). C1q, the natural ligand for gC1qR, is the first molecule to be
activated in the classical complement cascade and plays a critical role in
modulating both innate and adaptive immunity (Ghebrehiwet and others 2001).
Binding of C1q to gC1qR on T lymphocytes leads to suppression of T cell
responsiveness (Chen and others 1994); similarly, HCV core can inhibit T cell
responses through interaction with gC1qR (Yao and others 2001a; Yao and
others 2003; Yao and others 2004). Thus, the engagement of circulating HCV
core protein with gC1qR displayed on the surface of T lymphocytes may provide
the virus with a direct means of affecting host immunity (Yao and others 2001b).
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In light of the observations that free core particles circulate in the
bloodstream of HCV-infected patients (Masalova and others 1998; Maillard and
others 2001), our findings may be particularly salient to the pathogenesis of HCV.
It is notable that in addition to HCV core, gC1qR has been shown to interact with
several viral and bacterial proteins, potentially providing these organisms with a
“shared” mechanism of immune modulation (Ghebrehiwet and others 2001; Yao
and others 2001b). While the early events following the HCV core/gC1qR
interaction have yet to be elucidated, T cell receptor (TCR) signaling pathways-and in particular other negative regulatory pathways--would be prime targets for
viral immunomodulation.
The recently described PD-1 and PD-L inhibitory pathway represents just
such a negative regulatory mechanism to maintain the intricate balance between
positive and negative costimulatory signals delivered to T cells after antigenic
encounter (Nishimura and Honjo 2001; Khoury and Sayegh 2004). PD-1
(programmed death-1) is an immunoinhibitory receptor predominantly expressed
on activated T cells; its natural ligands include PDL-1 (also known as B7-H1,
expressed on both haematopoetic and parenchymal cells) and PDL-2 (B7-DC,
primarily expressed on monocytes). Activation of the PD-1 pathway induces
immunoreceptor tyrosine phosphorylation and recruitment of tyrosine
phosphatases, including src-homology proteins (SHP-1/SHP-2), to deliver a
negative signal to TCR activation pathways. Evidence is emerging for the
involvement of PD-1 inhibitory pathway in normal immune tolerance, autoimmune
responses, and antitumor and antiviral immune evasion (Nishimura and Honjo
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2001; Iwai and others 2003; Khoury and Sayegh 2004). Perhaps most
interesting, PD-1 was recently found to be selectively up-regulated on
“exhausted” CD8+ T cells during chronic viral infection in mice (Barber and others
2006). In addition, very recent reports now show similar findings in the setting of
HIV infection (Day and others 2006; Freeman and others 2006; Petrovas and
others 2006; Trautmann and others 2006b).
To further characterize underlying mechanism(s) of HCV-induced T cell
dysfunction, we examined the role of PD-1 and PDL-1 expression on human T
cells. We found that individuals with chronic HCV infection exhibit up-regulation
of both PD-1 and PDL-1 on CD4+ and CD8+ T cell populations compared to
healthy control populations. To explore potential mechanisms for this upregulation, we exposed naïve healthy T cells to HCV core and found that
expression of both PD-1 and PDL-1 are up-regulated, and this core-induced
PD-1 and PDL-1 induction is gC1qR-dependent. Importantly, blocking PD-1 and
PDL-1 signaling pathway can restore HCV core/gC1qR-mediated T cell function,
suggesting that the PD-1 pathway may be employed during HCV core/gC1qR
interaction as a means of dysregulating T cell functions.
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Materials and Methods

Subjects.

An IRB-approved protocol at ETSU has contributed to a database for the
storage of blood samples from HCV-infected individuals. Blood from healthy
donors serves as a normal control. Peripheral blood mononuclear cells (PBMC)
were isolated from these subjects by Ficoll density centrifugation with lympholyteH (Cedarlane Labs, Ontario, Canada) and then cryopreserved in freezing
medium (10% DMSO, 20% FBS in RPMI 1640) in liquid nitrogen until examined.
Twelve chronically HCV-infected patients and seven healthy donors were
selected, and their PBMC were thawed, washed, and counted for the following
studies. One subject was co-infected with HIV but was a long-term
nonprogressor with repeatedly negative HIV viral load. All subjects had HCV
infection detected by ELISA and confirmed by HCV RNA testing and none were
considered to be acute infections.

Reagents.

Recombinant HCV core protein, NS3, and control β-galactosidase proteins
were obtained from ViroGen (Watertown, MA). These proteins have been used
extensively in immunologic studies of HCV antigens and have been documented
to be free of LPS or RNA. Anti-CD3/CD28, anti-CD45RA/RO antibodies, and
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FITC-conjugated anti-CD4 and CD8 antibodies were obtained from BD
Pharmingen (San Diego, CA). Anti-PD-1 and anti-PDL-1 were obtained from
eBioScience.

Flow Cytometry.

To determine PD-1 or PDL-1 expression on the surface of T lymphocytes,
1 x 106 PBMC from HCV patients or healthy donors were stimulated with or
without anti-CD3/CD28 (1 μg/ml) in the presence of HCV core or a control
protein, β-gal (2 μg/ml). After 24 h treatment, the cells were washed in
fluorescence-activated cell sorting (FACS) medium (RPMI 1640 supplemented
with 10% FBS and 1% NaN3) at 200 x g for 5 min at 4 ºC. The cells were
counted and resuspended in 100 μl of FACS medium containing 20 μl PE-antihuman PD-1 and PDL-1 conjugate (eBioScience) and 20 μl of FITC-anti-human
CD4 and CD8 conjugate (BD Pharmingen) at 4 ºC for 1 h in the dark. The cells
were then washed three times and fixed with 1% paraformaldehyde in PBS
before analysis by flow cytometry (Becton Dickinson, San Jose, CA). The
primary isotype controls were used to determine the level of background staining.
20,000 events were collected after gating on lymphocyte populations and using
consistent instrument settings to avoid bias.
To determine the role of PD-1 and PDL-1 in HCV core-induced T cell
inactivation, PBMC were anti-CD3/CD28-stimulated and HCV core-treated as
described above in the presence of anti-human PD-1 or PDL-1 or isotype control
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antibodies (Santa Cruz) for 24 h, and CD69 cell surface expression was detected
by incubating cells with PE-anti-human CD69 conjugate (BD Pharmingen)
followed by FACS analysis (Yao and others 2003).

RT-PCR.

Purified PBMCs (2 x 106) were treated with or without HCV core protein (2
μg/ml; ViroGen) for various time points (6, 12, 24, 48 h), and total RNA was
isolated from these cells by the TRIzol method (Life Technologies). A total of 1
μg of RNA was treated with DNase to digest genomic DNA and 0.27 μg of RNA
was then reverse transcribed using MuLV reverse transcriptase under conditions
of 10 min at room temperature, 20 min at 42 ºC, 5 min at 99 ºC, and 5 min at
4 ºC. 1 μl of 1:10 serially diluted cDNA generated in the RT reaction was added
to the PCR reaction. PCR was carried out using the following primer pairs: PD-1
sense 5’-GCT CAG GGT GAC AGA GAG AAG-3’; antisense 5’-CAC CAA CCA
CCA GGG TTT G-3’; β-actin sense 5’-CGA GCG GGA AAT CGT GCG TGA
CAT-3’; antisense 5’-CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT-3’ for
35 cycles of 95 ºC for 15 s, 58 ºC for 15 s, 72 ºC for 15 s, followed by a single 10
min extension at 72 ºC. To control for genomic DNA contamination, equal
amount of cDNA from each sample were PCR amplified without RT. The
resulting PCR products were separated on a 2% BioGel (Bio 101, Carsbad, CA)
and viewed by a multimager. To examine whether gC1qR mediates the HCV
core-induced induction of PD-1, a 1:10-diluted anti-gC1qR antibody or pre-
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bleeding control serum (kindly provided by Dr. Hahn) was coincubated with cells
treated with core protein, and PD-1 mRNA expression was assessed as
described above.

T Cell Proliferation.

The ability of anti-PD-1 or anti-PDL-1 to reverse the HCV core-induced T
cell inhibition was evaluated by using Quick Cell Proliferation Assay (BioVision,
Mountain View, CA). Briefly, 1 x 105 of PBMC were stimulated with or without
anti-CD3/CD28 in the presence of HCV core or β-gal protein. Anti-PD-1 or antiPDL-1 or isotype control antibody (2 μg/ml, Santa Cruz) was added
simultaneously and the cells were cultured for 24 h. T cell proliferation was
performed according to manufacturers’ instructions. The absorbance of the
treated and untreated samples was measured using a microtiter plate reader at
420-480 nm with a reference wavelength 650 nm. The experiments were set up
as triplicates of each treatment and the data shown as mean ± SD of the optical
density (OD) values.

Cellular Apoptosis.

Blocking PD-1 and PDL-1 engagement to reverse the HCV core-mediated
lymphocyte apoptosis was assessed by Annexin V (AV)/Propidium iodide (PI)
staining (BD Pharmingen). Briefly, 1 x 106 PBMC were treated with HCV core or
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β-gal (2 μg/ml; ViroGen) in the presence or absence of anti-PD-1 or anti-PDL-1
or isotype control antibody (Santa Cruz) for 24 h. Cell apoptosis was examined
by FACS using an AV/PI staining kit according to manufacturer’s instructions.
The primary isotype controls were used to determine the level of background
staining. Twenty thousand events were collected after gating on lymphocyte
populations.

Statistical Analysis.

Data were shown as mean ± SD and level of significance was determined
using ANOVA as a program of Stata/SE 8.0 software. P < 0.05 was considered
significant.

Results

Increased Expression of PD-1 and PDL-1 on CD4+ and CD8+ T Cells of
Individuals with Chronic HCV Infection.

It has been reported that T cells adapt to persistent antigen exposure by
down-regulating their responsiveness to TCR signal transduction. Furthermore,
recent data suggest a key role for PD-1 in decreasing TCR signaling as a means
of promoting viral persistence. To determine if PD-1 might be playing a role
during HCV infection in humans, we examined PD-1 expression on T cells from
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chronically HCV-infected individuals (n=12) and compared these with T cells from
healthy donors (n=5). To this end, peripheral blood mononuclear cells (PBMC)
isolated from HCV patients and healthy donors were stimulated with or without
anti-CD3/CD28 antibodies, mimicking the activation of the TCR/CD28 pathway
by MHC/peptide/B7 complex on T cells. The cells were harvested at 24 hr after
the stimulation and the expression of PD-1 on the surface of T cells was
determined by flow cytometric analysis. As shown in fig. 2.1A, PD-1 expression
on the surface of unstimulated (39.02 ± 7.28) as well as anti-CD3/CD28stimulated PBMCs (54.01 ± 8.14) isolated from HCV patients is significantly
higher than the expression observed on the cells of healthy donors (17.88 ± 3.72,
P=0.002; 36.70 ± 9.17, P=0.005; respectively). Consistent with the aggregate
PBMC population data, the expression of PD-1 on the surface of distinct
subpopulations of CD4+ and CD8+ T cells from HCV patients is also higher than
that found on healthy donors, with representative dot blots shown in fig. 2.1B.
The expression of PDL-1 on PBMCs from HCV infected individuals was similarly
increased, with representative histograms shown in fig. 2.1C. Treatment with
other viral proteins, including HCV NS3 as well as HIV Tat and gp120, revealed
no effect on PD-1 expression levels in PBMC (data not shown).
It is possible that we started with different lymphocyte phenotype
subpopulations and that the increases in expression of PD-1 and PDL-1 are
related to different baseline phenotypes. Examination of PBMC from two HIVinfected subjects, however, revealed similar CD45RO+ and CD45RA+
subpopulations and increases in expression in PD-1 and PDL-1 upon TCR-
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stimulation (fig. 2.1D) This is consistent with our hypothesis that HCV infection
leads to up-regulation of PD-1 and PDL-1 expression via an interaction of HCV
core with gC1qR that is expressed on multiple T cell phenotypic subpopulations,
and that there is both HCV-specific and generalized T cell dysfunction in the
setting of chronic HCV infection.
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Figure 2.1 PD-1 expression on PBMCs from chronically HCV-infected individuals is increased
compared to healthy donors
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gC1qR-dependent PD-1 and PDL-1 Induction on Healthy T Cells by HCV
Core Protein.

The above data suggested that PD-1 and PDL-1 are up-regulated in
response in the setting of chronic HCV infection; how this occurs is unclear, but it
seems likely that a viral product induces this up-regulation. Because we have
previously shown that the HCV core nucleocapsid protein is both necessary and
sufficient to inhibit T cell responses against viral infection (Yao and others 2001a;
Yao and others 2001b; Yao and others 2003; Yao and others 2004), we
examined expression of PD-1 and its ligand, PDL-1, on healthy T cells exposed
to the HCV core protein. Peripheral blood mononuclear cells (PBMC) isolated
from healthy donors were stimulated with or without anti-CD3/CD28 antibodies in
the presence or absence of HCV core protein. To confirm that the complement
pathway is indeed involved in up-regulation of PD-1 signaling, we also treated
PBMC with C1q protein. The cells were harvested at 24 hr after treatment and
the expression of PD-1 and PDL-1 was determined by flow cytometric analysis.
As shown in fig. 2.2A, treatment of PBMC with C1q leads to an increase in PD-1
expression compared to control β-gal treatment in unstimulated PBMC; PDL-1
expression was also increased in response to C1q treatment (data not shown).
Both PD-1 and PDL-1 expression can be up-regulated on unstimulated
lymphocytes exposed to the HCV core protein (from 8% to 12%; and from 27% to
69%, respectively). Notably, PD-1 and PDL-1 expression are up-regulated on
lymphocytes stimulated with anti-CD3/CD28 (from 8% to 20%; and from 27% to
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70%, respectively), and their expressions can be further up-regulated with HCV
core treatment (from 20% to 28%; and from 70% to 92%, respectively). These
data revealed statistically significant differences. A titration analysis with HCV
core protein revealed a dose-dependent increase in PD-1 expression, with
minimal increases seen at 0.125 μg and saturation by 2 ug/ml of protein (data not
shown). Notably, while C1q treatment does appear to up-regulate the PD-1
pathway, HCV core appears to be more efficient at doing so. HCV core has,
however, been shown to have a higher affinity for gC1qR than C1q in previous
binding studies.
We next wanted to characterize the expression of PD-1 and PDL-1 on
specific human T cell subpopulations. PBMCs were treated as above, followed
by double staining with FITC-anti-human CD4 and PE-anti-human PD-1 and
PDL-1 conjugates. As expected based on the data in the aggregate lymphocyte
population, the expression of PD-1 and PDL-1 are up-regulated by HCV core
protein on both unstimulated and TCR-activated CD4+ T lymphocytes (fig. 2.2B).
CD8+ T cells revealed similar trends (data not shown).
To determine the relationship between HCV core and PD-1 expression,
we next detected PD-1 mRNA expression in PBMCs stimulated with antiCD3/CD28 in the presence or absence of HCV core protein for various times
after treatment using semi-quantitative RT-PCR. As shown in fig. 2.2C, PD-1
mRNA in human cells is consistently up-regulated, starting as early as 6 hrs and
peaking at 24 hrs after treatment with HCV core protein. Because we have
shown that HCV core protein impairs T cell functions through an interaction with
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the complement receptor, gC1qR, we employed anti-gC1qR antibodies in the
above experiments and found inhibition of HCV core-induced PD-1 up-regulation.
This reversal effect can be also achieved by addition of anti-HCV core antibody,
which interferes with the engagement of core protein with cell surface gC1qR, but
not by a control serum. To support these findings, healthy, TCR-stimulated
PBMC were treated with HCV core along with anti-gC1qR or control antibodies
and PD-1 expression was detected on the surface of healthy CD8+ T cells by
flow cytometry. PD-1 expression was diminished in cells treated with antibodies
to gC1qR, consistent with our PCR data in PBMC. Notably, treatment of PBMC
with anti-gC1qR antibodies alone has no effect on either PD-1 expression levels
as measured by flow cytometry or lymphocyte apoptosis as measured by AV
staining (data not shown). These results suggest that HCV core induces PD-1
expression directly through the gC1qR displayed on the surface of lymphocytes.
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Figure 2.2 PD-1 induction on healthy human T cells by HCV core protein
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Blocking PD-1 and PDL-1 Engagement Restores HCV Core/gC1qRMediated T Cell Dysfunction.

To explore the role of PD-1 and PDL-1 in the HCV core-induced T cell
dysfunction, we next addressed the possibility of restoring HCV core-mediated
inhibition of T cell function by blocking PD-1 and PDL-1 engagement. We have
previously shown that HCV core modulates T cell activation status, proliferative
capacity, and apoptosis (Yao and others 2001a; Moorman and others 2003; Yao
and others 2003; Yao and others 2004). To this end, we incubated TCRstimulated healthy PBMCs with HCV core protein in the presence of anti-PD-1 or
anti-PDL-1 or isotype control antibodies and assayed the above measures of T
cell function. We found that treatment of PBMC with anti-PD-1 or anti-PDL-1
antibodies alone had no effect on any of these measures and found no increase
in the ability to activate T cells despite blocking PD-1 and PDL-1 signaling (data
not shown). We first detected the expression of the T cell activation marker,
CD69, on the surface of T cells. As shown in fig. 2.3A, CD69 expression on
CD4+ and CD8+ T cells was suppressed by exposure to HCV core protein, and
this suppression was almost totally reversed by the treatment of anti-PD-1 or
anti-PDL-1 antibody. CD69 expression on T cells inhibited by HCV core was not
affected by adding control antibody.
We next examined T cell proliferation in response to HCV core in the
presence of antibodies to PD-1 and PDL-1. We incubated TCR-stimulated
PBMC with HCV core protein in the presence of anti-PD-1 or anti-PDL-1 or
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control antibody, and T cell proliferation was evaluated as described in Methods.
As shown in fig. 2.3B, T cell proliferation was inhibited by HCV core protein, and
the proliferative ability of T cells inhibited by HCV core could be partially restored
by simultaneously adding either anti-PD-1 or anti-PDL-1 antibody into the culture.
These data suggest that the PD-1 pathway plays a role in HCV core-induced T
cell suppression.
The induction of cellular apoptosis is one manifestation of HCV coremediated T cell dysfunction. To determine whether blocking PD-1 and/or PDL-1
engagement can reverse HCV core-induced cell apoptosis, we incubated human
PBMC with HCV core or control proteins in the presence of anti-PD-1, anti-PDL1, or a control antibody for 24 hrs, and apoptosis was evaluated by AV/PI
staining. As shown in fig. 2.3C (top), HCV core induces apoptosis, as
represented by increasing percentages of AV/PI positive cells, when compared
with those treated with a control protein, β-gal; this core-induced cell apoptosis
can be successfully blocked by the treatment with either anti-PD-1 or anti-PDL-1
antibody. These data are reproducible in multiple independent experiments
(bottom).
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Figure 2.3 Blocking PD-1 and PDL-1 engagement inhibits HCV core/gC1qR-mediated T cell
dysfunction
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Discussion

The most enigmatic facet of HCV infection is the fact that the majority of
individuals infected with this virus exhibit impaired T cell responses and develop
persistent infection, while a limited group are able to successfully control their
infections and experience spontaneous virus eradication. It is generally agreed
that both viral and host factors play a role in determining the outcome of viral
infection. Our previous studies (Yao and others 2001a; Moorman and others
2003; Yao and others 2003; Yao and others 2004) and current data would
suggest that HCV core protein may be a major viral antigen involved in
immunomodulating host responses. Intriguingly, HCV core is secreted from
infected cells and circulates in the bloodstream of infected individuals (Masalova
and others 1998; Maillard and others 2001) at levels consistent to those used in
our experiments. In addition, the amount of free core protein or core protein
expressed on the surface of infected cells is greater in the micro-environment of
the liver, where virus replication occurs quite vigorously in early infection when
chronicity is either avoided or established. Thus, HCV core protein appears to be
available in the setting of clinical infection and based on our studies could be
contributing to establishment of persistent HCV disease.
While it seems clear that HCV evades relatively weak host immune
responses, the issue of the level and specificity of immunosuppression in
individuals with HCV infection remains debatable. Several reports suggest that
selective dysfunction of HCV-specific T cells occurs in HCV-infected patients,
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with preservation of immune responses to unrelated viruses and/or antigens
(Gruner and others 2000; Takaki and others 2000; Thimme and others 2001;
Wedemeyer and others 2002). Other studies, however, have found
abnormalities with T cell responses to unrelated or nonspecific antigens in the
setting of HCV infection. For example, CMV-specific CD8+ maturation markers
were dramatically lost in an HCV-infected cohort despite the fact that inducible
responses to antigen were preserved (Lucas and others 2004). This study
suggested that HCV infection had a pervasive effect on numerous CD8+ T cell
populations and not merely HCV-specific T cells. Interestingly, a recent study in
an HIV/HCV co-infected cohort found that IFNγ secretion to recall antigens
including Candida (as well as HCV antigens) correlated with the degree of
hepatic fibrosis, with the data suggesting that impaired cellular responses were a
qualitative defect rather than a function of CD4 cell count (Graham and others
2005). It is by no means impossible that both HCV-specific and non-specific
immunodysregulatory mechanisms are occurring during acute and chronic HCV
infection, perhaps supported by the strong clinical evidence of autoimmune
disease associated with HCV infection (Manns and Rambusch 1999; Vogel and
others 2002).
Our data would support nonspecific immunomodulation of both CD4+ and
CD8+ T cell functions by HCV core antigen. We have in this and previous studies
consistently noted effects on T cell proliferation, activation, and apoptosis in
response to HCV core and dependent upon gC1qR engagement (Yao and others
2001a; Moorman and others 2003; Yao and others 2003; Yao and others 2004).
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This does not rule out the presence of HCV-specific T cell dysfunction by HCV
core or other viral gene products, and certainly further studies in this area are
warranted. It is also feasible that HCV core expression in the peripheral blood of
infected patients, while perhaps not sufficient to induce the severe, generalized
immunosuppression seen with HIV, may be high enough to reach a threshold
locally in the liver to facilitate persistent HCV infection.
The novel role of PD-1 and PDL-1 in HCV described herein is exciting and
may ultimately provide a marker and perhaps a mechanism by which such
viruses establish persistent infection. The recent studies of LCMV infection in a
murine model and HIV in humans clearly demonstrate a key role for PD-1 upregulation in CD8+ T cell exhaustion and control of viral infection (Barber and
others 2006; Day and others 2006; Freeman and others 2006; Petrovas and
others 2006; Trautmann and others 2006b). Our data in human T cells suggest
that that HCV might function in a similar model, with up-regulation of PD-1 being
associated with and perhaps contributing to chronicity. While it is certainly
possible that this up-regulation of PD-1 in chronically HCV-infected individuals is
more a marker of chronicity, there is little doubt that signaling via this pathway in
general leads to immunomodulation (Nishimura and Honjo 2001). We expect
that other chronic viruses may be associated with PD-1 up-regulation as well.
Once again, our data would suggest that up-regulation of the PD-1 and
PDL-1 pathway occurs in the general T cell population, but it would clearly be
worth pursuing an analysis of PD-1 expression in HCV-specific CD8+ and CD4+ T
cell populations from chronically infected individuals using tetramer studies and
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antibodies to PD-1 and PDL-1. Complicating these studies is the very real
technical challenge of analyzing virus-specific T cells that are often absent or
present at very low frequencies in individuals with chronic HCV infection (He and
others 1999); studies in this area are in progress but reversal of virus-specific T
cell dysfunction thus far has not been accomplished. It is possible that coreinduced up-regulation of PD-1 and PDL-1 might be occurring on antigen
presenting cells or hepatic tissues and promoting T cell dysfunction through cellcell interaction.
Our data demonstrated the ability to reverse T cell dysfunction in healthy
donor PBMCs exposed to HCV core by blocking PD-1 engagement, supporting a
link between HCV core, gC1qR, PD-1, and T cell functions. Whether this
reversal can occur in chronically infected HCV-infected individuals is no doubt
the most pressing question, but has thus far been technically challenging for us
to determine in infected individuals in the setting of years of chronic antigen
exposure and T cell anergy. The intracellular mechanism(s) linking these
pathways are also as yet unclear, but possibilities include SHP-1/2 or the SOCS
family that have been linked to negative regulation of T cell signaling pathways
(Balasubramanian and others 2003; Bode and others 2003). Studies addressing
these questions are ongoing.
We have thus found up-regulation of the PD-1 pathway in chronically
infected individuals with HCV that may be mediated through HCV core protein, a
known immunomodulatory viral antigen that circulates in the serum of infected
individuals. This study raises the possibility of targeting this inhibitory pathway
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for the treatment of persistent viral infections. Blocking either the gC1qR or PD-1
inhibitory pathways might be of clinical benefit during the acute phase of viral
infection when persistence is established in the majority of hosts. Restoring
impaired T cell function during chronic infection, albeit challenging, may be the
more desirable goal. This might be achievable based on limited evidence of
occasional resolution of HCV infection with increasing CD4+ T cell numbers and
function following HAART for HIV infection. Furthermore, the most common
reason for failure of therapeutic vaccine in eliminating chronic diseases is limited
T cell proliferative potential, and as such a better understanding of this novel
mechanism by which viruses impair T cell responses may open new avenues for
immunotherapy by inhibition of fundamental, negative regulatory pathways.
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Figure Legends

Figure 2.1 PD-1 Expression on PBMCs from Chronically HCV-infected
Individuals is Increased Compared to Healthy Donors.

A) PMBC were isolated from 12 chronically HCV-infected patients
(circles) and 5 healthy donors (squares). The cells were stimulated with (filled
circles or squares) or without anti-CD3/CD28 (anti-TCR stimulation, open circles
or squares) for 24 h, and PD-1 expression on lymphocytes was examined as
described in Materials and Methods. Percentage of PD-1+ cells in the gated
lymphocyte population was shown. Statistical comparison (p values) amongst
different groups, including PD-1 expression on T cells from chronic HCV patients
versus healthy donors as well as unstimulated cells versus TCR-stimulated cells,
are all < 0.01. Data represent cumulative results of three independent
experiments. B) Representative dot blots from subjects showing percentages of
PD-1+ cells in the TCR-stimulated CD4+ and CD8+ T lymphocyte populations.
Lymphocytes were double-stained and gating was performed on distinct
populations of either CD4+ or CD8+ cells. Isotype controls for these experiments
are shown. C) Representative histograms of PDL-1 expression on unstimulated
lymphocytes from HCV-infected or healthy subjects. D) PD-1 and PDL-1
expression on different PBMC phenotype populations. PBMC from 2 chronic
HCV patients were subjected to mock stimulation or TCR-activation and PD-1
and PDL-1 expression on CD45RA+ and CD45RO+ populations were detected by
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flow cytometric analysis. Percentages of PD-1 and PDL-1 on CD45RA+ and
CD45RO+ lymphocytes are shown on the upper right corner.

Figure 2.2 PD-1 Induction on Healthy Human T Cells by HCV Core
Protein.

A) PD-1 induction on lymphocytes by C1q protein and HCV core protein.
Left, unstimulated PBMC from healthy donors were exposed to C1q or a control
protein β-gal for 24 hr, and PD-1 expression on the surface of the treated
lymphocytes was examined as described in Methods. The percentages of PD-1
expression on lymphocytes are shown and the data are representative of
experiments from two separate donors. Middle and right, unstimulated or TCRstimulated PBMC from healthy donors were exposed to HCV core or a control
protein β-gal for 24 h, and PD-1 and PDL-1 expressions on the surface of the
treated lymphocytes were examined as described in Methods. The percentages
of PD-1 or PDL-1 expression on PBMCs are shown and are representative of
three independent experiments. Cumulative analysis of these experiments
revealed statistical significance between β-gal- and β-gal core-treated
unstimulated cells and stimulated cells (unstimulated PD-1: 10.09 ± 2.7 vs 16.5
± 5.03, p<0.05; stimulated PD-1: 18.05 ± 2.9 vs 32.15 ± 5.3, p<0.05;
unstimulated PDL-1: 31.27 ± 19.98 vs 58.60 ± 16.03, p<0.05; stimulated PDL-1:
65.9 ± 5.6 vs 90.75 ±2.3, p<0.02). B) PD-1 and PDL-1 induction on the CD4+ T
cell subpopulation by HCV core protein. Unstimulated or TCR-stimulated PBMC
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from healthy donors were exposed to HCV core or control protein β-gal for 24 h,
and PD-1 and PDL-1 expression on the surface of the treated CD4+ T
lymphocytes were examined as described in Methods. Cells were doublestained and gating was performed on a distinct CD4+ population; data shown are
representative dot blots from three independent experiments. The percentages
of PD-1 or PDL-1 expression on CD4+ T lymphocytes are shown. C) Time- and
gC1qR-dependent PD-1 mRNA induction by HCV core protein. Above, TCRactivated PBMC were treated with or without HCV core in the presence or
absence of anti-HCV core, anti-gC1qR or a control antibody for various time
points and PD-1 expression was detected by semi-quantitative RT-PCR as
described in the Methods. β-actin serves as a control. Results are
representative of two independent experiments. Below, flow cytometric analysis
of gC1qR-dependent PD-1 induction on CD8+ T cells by HCV core protein.
PBMC from 2 healthy donors were TCR-stimulated and treated with HCV core in
the presence or absence of anti-gC1qR or a control antibody for 24 hr, and PD-1
expression on CD8 + T cells was analyzed by flow cytometry. Percentage of PD1+ cells in the CD8+ populations is shown on the upper right corner.

Figure 2.3 Blocking PD-1 and PDL-1 Engagement Inhibits HCV
Core/gC1qR-mediated T Cell Dysfunction.

A) Blocking PD-1 pathway signaling restores the expression of the early T
cell activation marker CD69 that is inhibited by HCV core. PBMC were
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stimulated with anti-CD3/CD28 in the presence of HCV core or control protein βgal for 24 h. Anti-PD-1 or anti-PDL-1 antibody was added to the TCR-stimulated
and core-treated cells simultaneously. T cell activation was assessed by
detecting CD69 expression on the surface of CD4+ and CD8+ T lymphocytes as
described in Methods. Isotype controls for staining are shown. Results are
representative of two independent experiments with separate donors. In the
CD4+ subpopulation, statistical significance was observed between β-gal and βgal-core-treated cells (55.6 ± 3.7 vs 13.2 ± 2.7, p<0.01), between β-gal-coretreated cells and β-gal-core-treated cells with antibody to PD-1 (41.5 ± 11.1 vs
13.2 ± 2.7, p<0.04), and between β-gal-core-treated cells and β-gal-core-treated
cells with antibody to PDL-1 (57 ± 8.1 vs 13.2 ± 2.7, p<0.01). B) Blocking PD-1
pathway prevents HCV core-induced inhibition of T cell proliferation. PBMC were
stimulated with or without anti-CD3/CD28 in the presence or absence of HCV
core protein for 24 h. Anti-PD-1 or anti-PDL-1 antibody was added to the TCRstimulated and core-treated cells simultaneously. T cell proliferation was
assessed by Quick Cell proliferation assay. Statistical significance is shown and
results are derived from three independent experiments with separate donors.
C) Blocking PD-1 pathway prevents HCV core-induced T cell apoptosis. PBMC
were TCR-stimulated in the presence or absence of HCV core protein for 24 h.
Anti-PD-1 or anti-PDL-1 antibody was added to the TCR-stimulated and coretreated cells simultaneously. T cell apoptosis was assessed by AV/PI staining as
described in Methods. Above, percentages of cells in the early apoptotic stage
(only AV positive) and in death (AV/PI double positive) after the treatment are
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shown. Below, the data were shown as percentage of cells positive for AV or PI
(mean ± SD) on the gated T cell populations from six independent experiments
with separate donors. * denotes statistical significance when compared to
control treatment (p<0.01).

†

denotes statistical significance when compared to

HCV core treatment (p<0.01).
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CHAPTER 3

Hepatitis C: the Complications of Immune Dysfunction

Summary

Hepatitis C virus (HCV) infection has been linked to numerous diseases of
immune dysfunction, including but not limited to essential mixed cryoglobulinemia
and non-Hodgkin’s lymphoma. Clinical studies support these associations and
treatment of the underlying HCV infection has been variably successful. Recent
studies focusing on the role of HCV gene products have discovered evidence of
dysregulated responses in multiple aspects of host immunity that may be
contributing to the genesis of these diseases. Novel treatments that target these
areas of dysregulation offer hope for improved therapy for the diseases
associated with immunodysregulation by HCV.

Introduction

HCV was identified as the agent of transfusion related non-A, non-B
hepatitis in 1989 (Choo and others 1989). The Centers for Disease Control and
Prevention estimate 2.7 million Americans have chronic hepatitis C infection with
an annual monetary cost (medical and work loss) of >600 million dollars. The
majority of acute cases occur in adults 30-49 years old and HCV infection is the
leading indicator for liver transplant in the U.S. and Europe (Alter and others
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1997; Hoofnagle 1997). Persons who have chronic hepatitis C infection are at
significant risk of developing cirrhosis, hepatocellular carcinoma and notably
diseases of immune dysfunction, including essential mixed cryoglobulinemia and
lymphoproliferative disorders (Hoofnagle 1997), upon which this review will
focus. Disease progression varies greatly from person to person, making it not
only difficult to predict who will develop chronic disease but also which of the
chronically infected will go on to develop significant sequelae. To further
compound the issue, it appears that the six major genotypes described may have
differing disease patterns and responses to treatment (Simmonds and others
1993b).
Hepatitis C is a 9.5-kb, positive strand, RNA virus of the Flaviviridae
family. The genome consists of ~9500 nucleotides encoding a single polyprotein
of ~3000 amino acids that is cleaved into structural and non-structural proteins.
It encodes three structural proteins (core, E1 and E2) and at least six nonstructural proteins (Figure 3.1).

Figure 3.1 HCV genomic structure

HCV is classified into 6 genotypes with over 30 subtypes based on sequence
variation in the core and E1 genes, additionally, there are significant
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geographical variations (Simmonds and others 1993b). Persons with long-term
infections tend to have greater levels of genetic diversity within their genotypes
(quasispecies) (Farci and others 1997), most likely due to the poor fidelity of the
HCV RNA polymerase. The phenomena of high levels of quasispecies is
associated with poor clinical prognosis, which may be linked to the poor cytotoxic
lymphocyte (CTL) response in chronically infected persons.
In the U.S., HCV genotypes 1a and 1b are most prevalent and the most
resistant to the currently available therapy, pegylated interferon-α (IFN-α) and
ribavirin (Hoofnagle 2003). This combination treatment will induce a sustained
virologic response (SVR) in 42-48% of persons infected with genotype 1a or 1b
but up to 76-88% of persons infected with genotypes 2 or 3 (Fried and others
2002). Side-effects, however, are common and can be serious. For example,
IFN-α is associated with significant depression and ribavirin can induce anemia
and neutropenia and is teratogenic.
The study of HCV is made difficult by two key factors. HCV will only
reliably infect humans and chimpanzees, thus limiting animal models, and in vitro
replication is very poor (although some replicon systems have been functional in
hepatocytes.) Since newly infected persons are often asymptomatic and
therefore are rarely clinically recognized as infected, it has also been difficult to
determine the initial immune responses that correlate with viral clearance.
Finally, because diseases associated with immune dysfunction occur frequently
in individuals without HCV infection, it has been difficult to confirm strong
associations between HCV and a given disease. This review will describe the
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common diseases of immune dysfunction associated with HCV infection and
discuss potential mechanisms underlying these diseases.

Potential Mechanisms of HCV-mediated Immune Dysfunction
While the precise mechanisms for how the disruption of the host immune
response by HCV can result in various immune disorders have yet to be defined,
it is apparent that HCV modulates host immunity on several different levels
(Moorman and others 2001b). Over the past decade, there have been numerous
studies examining different facets of HCV-associated immune dysfunction which
have included B-cell, T-cell, NK cell, and dendritic cell dysregulation (Figure 3.2).
The significance of such immunomodulatory potential appears to be twofold:
evasion of the host immune response leading to viral chronicity, and the potential
for development of lymphoproliferative disorders.
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Figure 3.2 Proposed model for immune dysregulation by HCV infection

It is noteworthy that HCV clearly infects multiple extrahepatic cell types,
including peripheral blood mononuclear cells, and this is observed both in vivo
and in vitro (Shimizu and others 1992; Shimizu and others 1997; Lerat and
others 1998; Radkowski and others 2000; Radkowski and others 2002; Nowicki
and others 2005). It is therefore possible that the immune dysfunction observed
in HCV is a function of its ability to infect such cells, although the frequency of
this infection appears low. HCV sequences observed in different cellular
compartments and in particular peripheral blood mononuclear cells may vary,
suggesting viral tropism for specific cells that may be in part affected by the HCV
diversity that occurs as quasispecies develop (Lerat and others 1998). The role
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of a given genotype in targeting hematopoetic cells remains controversial (Kao
and others 1997; Lerat and others 1998).

Dysregulation of B Cell Function Mediated by HCV
Since the association between chronic HCV infection and both mixed
cryoglobulinemia and B-cell lymphoma was first recognized, there have been an
increasing number of studies examining B cell dysfunction in the context of
chronic HCV infection. While it has clearly been shown that clonal populations of
B lymphocytes are disproportionately present in increased numbers in patients
with chronic HCV infection, there are also numerous data detailing specific
mechanisms behind B cell clonality. Moreover, such mechanisms offer insight
into the presence of immune dysfunction in patients with chronic HCV infection.
Most notably, B cells have become a target of drug development for the
treatment of certain HCV-associated immune diseases (Kazkaz and Isenberg
2004).
Franzin et al. were the first to report the presence of clonal B cell
expansion in the peripheral blood of 38 HCV-infected patients (Franzin and
others 1995). Subset analyses in their study revealed the presence of clonal
immunoglobulin gene rearrangements in 100% of HCV-positive patients with type
II mixed cryoglobulinemia (MC) as opposed to only 24% of HCV-positive patients
without mixed cryoglobulinemia. The reversibility of B cell clonality in chronic
HCV infection was similarly assessed in a cohort of 20 patients with HCVassociated MC undergoing interferon-α therapy (Mazzaro and others 1996).
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While 80% of these patients (all of whom were noted to have clonal populations
of B cells) achieved complete or partial clinical responses, 15% reverted to
polyclonal B cell populations following therapy. Recent studies also suggest
upregulation of B-lymphocyte stimulator (BLyS) in the setting of MC (Fabris and
others 2006; Sene and others 2006), further supporting a significant relationship
between clonal expansion of B lymphocytes and HCV-associated mixed
cryoglobulinemia. Zignego et al. found an increased frequency of bcl-2 gene
rearrangement(t(14;18) in a prospective study of individuals with HCV and mixed
cryoglobulinemia (Zignego and others 2002), described in detail below. While
Toubi et al. observed enhanced B cell apoptosis in B cells from chronically
infected HCV patients, there was relative resistance to apoptosis seen in the
CD95/Fas+ B cell subpopulation, suggesting a potential role for this
subpopulation in B cell proliferative disorders (Toubi and others 2004).
As the propensity of HCV to induce lymphoproliferation in patients with
HCV-associated mixed cryoglobulinemia has been further elucidated, there has
been some effort to define the underlying mechanisms. Machida et al. reported
that an HCV E2-CD81 interaction modulates host B cell responses by enhancing
activation-induced cytidine deaminase (AID) and hypermutating V(H)
immunoglobulin genes in B cells, suggesting a mechanism for HCV-associated B
cell lymphoproliferative disorders (Machida and others 2005). HCV E2 was also
shown to activate the JNK pathway leading to preferential proliferation of CD27+
B cells (Rosa and others 2005).
The effect of HCV core protein on molecular profiling in human B-

77

lymphocytes was recently examined by Wu et al., who found dramatic evidence
of inhibition of B lymphocyte apoptosis by HCV core in several steps of the
apoptotic cascade (Wu and others 2006). The investigators expressed HCV core
in an adenoviral vector in a healthy population of human B lymphocytes and
observed downregulation of MHC class II molecules, and caspase-1 and -4,
which are proapoptotic proteins; as well as upregulation of nuclear factor of κ
light peptide inhibitor gene and TATA box protein, both of which are associated
with B cell lymphoma. Similarly, we have very recently found a differential
response of B cells and T cells to HCV core protein, with upregulation of B cell
functions (immunoglobulin expression and cell proliferation) and inhibition of B
cell apoptosis in the setting of downregulated T cell responses (personal
communication, JPM). These findings underscore the potential of HCV to disrupt
antigen presentation and apoptosis and may indicate yet another mechanism for
HCV-related autoimmunity and lymphoproliferation.
Oncogenes have also been a focus of investigation in patients with MC.
In a prospective study of 37 patients with HCV-associated mixed
cryoglobulinemia, Zignego et al. found that 75.7% had bcl-2 rearrangement in
peripheral blood mononuclear cells, as opposed to 37.6% of patients with chronic
HCV infection without mixed cryoglobulinemia (Zignego and others 2002). GalliStampino et al. further expanded on the relationship between oncogenesis and
clonal B cell expansion in patients with HCV-associated mixed cryoglobulinemia
by demonstrating the presence of restricted V(H)I gene sequences in peripheral
blood, hepatic, and lymph node B lymphocytes in three of four patients (Galli-
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Stampino and others 2003). These gene sequences are usually associated with
B-cell non-Hodgkin’s lymphoma and their presence in patients with chronic HCV
patients may indicate a mechanism of developing NHL through non-malignant,
clonally expanded B-cell populations.

Type I Interferon Dysregulation
Interferon-α (IFN-α) stimulation is a critical and non-specific response to
viral infection. Its two main effects are induction of an anti-viral state in infected
cells and interferon receptor ligation which results in activation of Janus kinase
(Jak) and signal transducer and activator of transcription (STAT). Jak/STAT
signaling in turn activates numerous interferon-response genes including 2’-5’
oligoadenylate synthetase (OAS), Mx proteins and the double-stranded RNA
dependent protein kinase (PKR) (Katze 2002). PKR is induced by double
stranded viral RNA and in-turn, phosphorylates eukaryotic initiation factor 2 (elF2), resulting in inhibition of cellular protein syntheses and viral replication. Two
HCV proteins, the envelope glycoprotein E2 and the nonstructural protein NS5A,
have been reported as potential inhibitors of the IFN response (Taylor 2000;
Pflugheber and others 2002).
Phosphorylated interferon factor 3 (pIRF-3) is the key transcription factor
for type I interferon (Foy and others 2003). Type I interferon in turn, upregulates
the expression of PKR. Recently, the HCV protein NS3/4A (a serine protease)
was shown to interrupt the IFN signaling pathway; thus, IRF-3 is never
phosphorylated and IFN production is not induced (Foy and others 2003). The
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importance of IRF-3 was also demonstrated with mutations resulting in dominant
negative or constitutively active IRF-3 leading to enhanced or restrained HCV
replication, respectively.

Dysregulation of the NK Response
Natural killer (NK) cells play a critical role in innate immunity. NK cells
mediate lysis of target cells by releasing cytotoxic granules which contain perforin
and granzymes or by binding apoptosis inducing receptors on the target cells.
NK cells also secrete numerous cytokines including IFN-γ and TNF-α during
inflammation (Poccia and others 2001). Recent reports have implicated the HCV
E2 protein in suppression of NK activity (Crotta and others 2002; Tseng and
Klimpel 2002).
The HCV E2 protein binds CD81 which is expressed on the surface of
host cells. When NK cells are exposed to immobilized E2 or anti-CD81 (in vitro),
their function is impaired. The impairment ranges from suppressing of
cytotoxicity and IL-2 induced proliferation to suppressing IL-2, IL-12 and IL-15
induction of IFN-γ (Crotta and others 2002; Tseng and Klimpel 2002).
Additionally, ligation of CD81 inhibits CD16-mediated activation of extracellular
signal-regulated kinase (ERK) and mitogen-activated protein kinase (MAPK) in
NK cells (Crotta and others 2002). These mechanisms, if employed by HCV,
could facilitate HCV persistence. However this possibility needs further research
as NK cells do not play a role in all viral infections.
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Dysregulation of Dendritic Cells by HCV Envelope Glycoproteins
One possible cause of an impaired CD8+ response to HCV infection may
be abnormal dendritic cell (DC) function preventing appropriate antigen
processing and presentation. Interestingly, HCV E1 and E2 glycoproteins
interact with DC-specific intercellular adhesion molecule 3 (ICAM-3), grabbing
nonintegrin (DC-SIGN) and its receptor, DC-SIGNR in immature DCs (Lozach
and others 2003; Pohlmann and others 2003). The role of HCV interactions with
DC remains controversial. Numerous studies demonstrate abnormal DC activity
in chronic HCV patients, yet recent studies by Longman et al. report the converse
(Longman and others 2005).
In addition to envelope proteins, HCV core has also been implicated in
inhibiting DC and macrophage function (Sarobe and others 2003). Addition of
extracellular core or expression of core/E1 in mice by recombinant adenovirus
demonstrated an effect on DC maturation and T cell responses upon allogenic
stimulation. A molecular mechanism(s) has not fully elucidated to explain this
inhibition.

Dysregulation of T Cell Function Mediated by HCV Core Protein
Patients who have a strong and broad cytotoxic lymphocyte (CTL)
response are more likely to spontaneous resolve a HCV infection when
compared to those with a weaker response (Lechner and others 2000). The CTL
response is suppressed during all phases of HCV infection, although the
suppression mechanism(s) are not well understood. One hypothesis for weaker
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CTL responses is that the HCV proteins interact either directly or indirectly
against CTLs. Data have been published indicating that HCV core antagonizes
host T cell responses, thus potentially contributing to disease progression (Large
and others 1999b; Ray and Ray 2001).
HCV core appears to interact with at least two major cellular signaling
pathways: intracellular core interacts with tumor necrosis factor receptor (TNFR)
and Fas, and extracellular core interacts with the complement receptor gC1qR
(Kittlesen and others 2000). Interactions between core and TNFR or Fas are
known to induce apoptosis in both hepatocytes and lymphocytes, suggesting a
possible mechanism for HCV-associated liver pathology (Hahn and others 2000;
Zhu and others 2001; Moorman and others 2003). However, whether the liver
pathology results from core-induced apoptotic hepatocytes or is a secondary
necrosis induced by infiltration of apoptotic lymphocytes remains to be
determined.
Intracellular core appears to localize to the cytoplasm, ER and nucleus,
while extracellular core is found in transfected cell lines and in the serum of
infected patients (Sabile and others 1999; Maillard and others 2004). This same
extracellular core has also been found to interact with the complement receptor
gC1qR, which results is inhibition of T cell activity (Kittlesen and others 2000).
This inhibition appears to take place early in infection and targets T cell
proliferation and IFN-γ production (Yao and others 2001a). C1q, the natural
ligand for gC1qR, is part of the C1 complex and is the first component in the
classical complement pathway. C1q, like HCV core, will also inhibit T cell
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proliferation, suggesting that core may usurp this pathway to its advantage.
Other viruses such as Epstein Barr and HIV appear to exhibit similar
mechanisms to suppress the host immune response by interactions with the
complement system (Hilleman 2004).
While HCV core appears to be a useful target as an antigenic stimulus
because of its highly conserved nature, this protein has also been associated
with the development of auto-antibodies such as anti-LKM, anti-p450, and antiGOR. Interestingly, alteration of core antigen to remove the molecular mimic
sites responsible for induction of these auto-antibodies was recently used to elicit
strong antigen-specific CTL responses with less self-recognition (Liu and others
2006).

HCV and the Associated Clinical Diseases of Immune Dysfunction
At least 36 extrahepatic disease manifestations have been associated with
HCV infection, with disorders of immune function frequently described (Table
3.1). With the exception of mixed cryoglobulinemia, acceptance of other disease
associations with HCV infection is not universal (Agnello 1997), but many have
fairly strong anecdotal support in the literature. While the data linking HCV
infection with non-Hodgkins lymphoma (NHL) is strong, the mechanism(s)
underlying the association remain poorly understood (Gisbert and others 2003).
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Table 3.1 Extrahepatic disease manifestations associated with HCV infection

Antiphospholipid syndrome

MALToma

Aplastic anemia

Membranoproliferative glomerulonepritis*

Autoimmune hemolytic anemia

Membranous glomerulonephritis

Autoimmune thyroiditis

Mixed cryoglobulinemia*

Chronic fatigue syndrome

Moorne corneal ulcers

Behcet’s syndrome

Multiple myeloma

Carotid atherosclerosis

Non-Hodgkin’s lymphoma (NHL)*

CREST syndrome

Neurocognitive impairment

Dermatomyositis

Pancreatitis

Diabetes mellitus

Polyarteritis nodosa

Fibromyalgia

Polymyositis

Guillain-Barre syndrome

Phophyria cutanea tarda

Hypertrophic cardiomyopathy

Rheumation arthritis

Hypocholesterolemia

Sialadenitis

Idiopathic pulmonary fibrosis

Sjogren’s syndrome

Idopathic thrombocytopenia purpura Systemic lupus erythematosus
IgA deficiency

Uveitis

Lichen planus

Waldenstrom’s macroglobulinemia

*Presented in greater detail in the text.
CREST: calcinosis Cutis, Raynaud’s phenomenon, esophageal dysfunction, sclerodactyly and
telangiectasia; HCV: Hepatitis C infection; MALT: Mucosa-associated lymphoid tissue
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Mixed Cryoglobulinemia (Type II Cryoglobulinemia)

Disease.

Cryoglobulinemia is defined as the presence of circulating
immunoglobulins (Ig) that reversibly precipitate at <37°C. The term “mixed
cryoglobulins” was coined to differentiate types II and III, which is characterized
by a mixture of 2 different kinds of antibodies, from type I, characterized by just a
single monoclonal antibody. Cryoglobulins may precipitate in vivo in small blood
vessels (venules, capillaries, arterioles), leading to vasculitis. The evidence
linking HCV and mixed cryoglobulinemia (MC) is strong and is supported by
epidemiological, molecular, and virological studies.

Prevalence.

In the early 1990s, multiple investigators reported the presence of HCV
infection in 50-90% of MC patients (Ferri and others 1991; Agnello 1997). The
frequency of dual status exhibits geographic variation, with southern Europe
having a higher rate than northern Europe or North America (Cacoub and others
2000). The most likely explanation for this difference is differing laboratory
techniques used to identify cryoglobulins. This hypothesis is supported by the
fact that regions that reported a higher frequency of HCV with MC generally used
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more sensitive laboratory methods to identify MC and consistent use of these
more sensitive methods has revealed increasing prevalence rates over time.
One alternative to using the more sensitive methods for detecting
cryoglobulins is to test for rheumatoid factor (RF). RF displays a high avidity for
IgG and thus easily forms immune complexes. Common tests for RF are
generally much more sensitive than tests for cryoglobulins. This was
demonstrated when data from 408 patients infected with HCV revealed that 40%
were positive for cryoglobulins, yet 100% were positive for RF (Karlsberg and
others 1995). HCV is now linked to approximately 73% of all forms of
cryoglobulinemia (Trejo and others 2001). Notably, the presence of
cryoglobulinemia is highly associated not only with extrahepatic disease, as
described below, but also with the development of cirrhosis (Kayali and others
2002).

Clinical Manifestations.

Traditionally, the presence of purpura, arthralgias, and weakness were
used to diagnose MC; this is no longer adequate as other symptoms are now
known to be associated with MC as well (Table 3.2) (Mayo 2003). Many persons
with detectable cryoglobulins display no obvious symptoms. When present, the
classic skin rash is a palpable purpura that may rarely progress to a necrotizing
lesion or systemic vasculitis. Arthralgias are a common complaint of persons
with MC and most often affect the proximal interphalangeal joints,
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metacarpophalangeal joints, and knees. In some cases, exposure to cold
temperatures will increase the pain and stiffness in these areas. Changes in
renal function and peripheral neuropathies are also more common than
previously thought.
Table 3.2 Symptoms of cryoglobulinemia

Symptom

Incidence

Skin disease

22%

Joint disease

16%

Weakness

65%

Renal disease

25-30%

Raynaud phenomenon

3-50%

Neuropathy

8-25%

Sicca syndrome

20%

Lymphadenopathy

3%

Fever

3%

Adapted from: (Dickson 1997; Hoofnagle 1997; Lunel and Musset 2001; Schott and others 2001; Raanani
and Ben-Bassat 2002; Mohammed and Rehman 2003; Nocente and others 2003; Han 2004; Ramos-Casals
and Font 2005; Vassilopoulos and Calabrese 2005; Vigani and others 2005)

Notable differences are observed when HCV-associated MC (HCV-MC)
patients are compared to MC patients without HCV infection. Both groups
display the same frequency of cutaneous involvement, renal involvement and
peripheral neuropathy, but the HCV-MC patients are less likely to manifest fever,
lymphadenopathy, articular involvement, or Raynaud’s phenomenon. ANA and
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RF are common in both groups, but MC patients without HCV are more likely to
have ANA, whereas HCV-MC patients are more likely to have RF (Trejo and
others 2001). Circulating immune complexes will activate complement and
therefore low levels of C3, C4, and CH50 are seen in all patients with MC.
However, the levels of C4 and CH50 are significantly lower in HCV-MC versus
non-HCV-MC patients (Trejo and others 2001).

Pathogenesis.

The symptoms of MC are due the vascular deposition of the
cryoprecipitate, which contains HCV-RNA, LDL, VLDL, IgG and monoclonal IgM
that has RF activity; these deposits can then lead to vasculitis. The importance
of HCV infection in this process is demonstrated by the increased levels of virus
and RF antibody (up to 1000 fold higher) at the site of vascular lesions when
compared to serum levels (Agnello and others 1992). Persons with HCV-MC can
also present with abnormal B cell proliferation, as described in detail above,
which appears to be an antigen driven process that can ultimately result in a
dominant B cell clone. This may be the result of genetic mutation; for example,
88% of patients who are HCV-MC demonstrate a translocation of the bcl-2 gene
from chromosome 18 to chromosome 14, compared to 8% of patients with HCV
alone and 2% of patients with other liver diseases (Zignego and others 2002).
However, translocation has not been shown to be a definitive cause, since bcl-2
overexpression does not always accompany t(14;18) translocation
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(Papakonstantinou and others 2001). B cells with the t(14:18) translocation
without bcl-2 overexpression and mRF B cells that over express bcl-2 without the
t(14:18) translocation may be present in the blood. The two populations cannot
be discerned without isolation studies that thus far have not been performed.

Management

Prior to the recognition that HCV is associated with MC, plasmapheresis in
conjunction with high-dose corticosteroids and immunosuppressive therapy was
employed to treat symptomatic exacerbations of the disease; there is a paucity of
evidence showing long-term benefit from such an approach (Ballare and others
1995). Plasmapheresis remains the cornerstone of therapy in the setting of MCassociated renal failure, limb ischemia attributable to cryoglobulinemic vasculitis,
and progressive motor neuropathy. Observational data suggests that
plasmapheresis can halt the progression of acute renal failure in 55% to 87% of
patients, although there is no clear mortality benefit (Madore and others 1996).
Corticosteroids are also generally advocated in patients with progressive renal
failure or vasculitis, although there are data suggesting that they may increase
HCV RNA viremia (Dammacco and others 1994).
Antiviral therapy directed towards chronic HCV infection has been shown
to be highly effective in HCV-associated MC. Interferon-α or pegylated
interferon-α in combination with ribavirin have been used successfully in this
manner (Table 3.3) (Zuckerman and others 2000; Mazzaro and others 2003;
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Cacoub and others 2005; D'Amico and others 2005; Mazzaro and others 2005).
Cacoub et al. reported complete clinical responses in eight of nine patients with
HCV-MC at 18 month follow-up after treatment with pegylated interferon-α plus
ribavirin for a mean of 13.5 months (Cacoub and others 2005). Mazzaro et al.
also reported favorable responses in eighteen patients with HCV-MC treated with
pegylated interferon-α plus ribavirin, although 44% (8 patients) relapsed both
virologically and clinically within a few weeks after cessation of therapy (Mazzaro
and others 2005).
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Table 3.3: Summary of trials examining interferon-α (IFN-α) or pegylated IFN-α with ribavirin in
the setting of HCV-associated mixed cryoglobulinemia

Year

Authors

No. of
Treatment Complete
patients
Virologic
Response*
(%)

Complete
Immunologic
Response**
(%)

Complete
Clinical
Response
(%)

Sustained
Response
(Clinical or
Immunologic)
(%)

2005 D’Amico et
al

25

100

96

ND

ND

2005 Cacoub et
al.

9

78

56

89

89-100

83

56-100

89

44

18

33

85

30

22

78

100

ND

2005 Mazzaro et 18
al.

2003 Mazzaro et 27
al.
2000 Zuckerman 9
et al.

IFN-α
plus
ribavirin
(6 – 12
months)
Pegylated
IFN- α
plus
rivavirin
(10 – 26
months)
Pegylated
IFN-α
plus
rivavirin
(48
weeks)
IFN-α
plus
rivavirin
(1 year)
IFN-α
plus
rivavirin
(6
months)

ND- no data
*Defined in all studies as achievement of undetectable viral load
**Reduction in cryocrit or rheumatoid factor concentration
Adapted from: (Zuckerman and others 2000; Mazzaro and others 2003; Cacoub and others 2005; D'Amico
and others 2005; Mazzaro and others 2005)

Rituximab, which is a chimeric monoclonal antibody directed towards
CD20, is a novel therapy to be tried in HCV-associated MC and appears to be
useful based on limited but numerous anecdotal studies (Zaja and others 1999;
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Basse and others 2005; Bruchfeld and others 2006; Quartuccio and others
2006a; Scheinfeld 2006; Seror and others 2006).

Non-Hodgkin’s Lymphoma

Disease.

Each year, 54,000 people in the United States are diagnosed with nonHodgkin’s lymphoma (NHL). NHL is a set of malignant diseases arising from
lymphoid tissues (B or T lymphocytes). Given the multiplicity of subsets of NHL,
epidemiological studies regarding causative factors have not been satisfactorily
conducted in comparison to other malignant diseases. However, several
possible causative factors have been identified, including pesticides, blood
transfusion, immunodeficiency, radiation, smoking and several types of diet, as
summarized previously (Matsuo and others 2001).

Prevalence.

The data linking HCV infection to NHL are significant but show
considerable variation (0-42%) (Kashyap and others 1998; Germanidis and
others 1999). Epidemiologic studies support a role for HCV in the development
of NHL as well as multiple myeloma (Ohsawa and others 1999; Duberg and
others 2005), but others have failed to show significance (Rabkin and others
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2002). An interesting parallel is data showing that random bone marrow biopsies
of HCV positive persons reveal a lymphoproliferative disorder 25-40% of the time
(Ferri and others 1994; Rasul and others 1999). One case control study from
Italy found that HCV infection increased the risk for NHL 50-fold in the liver or
salivary glands--greater than the relative risk for hepatocellular carcinoma. The
same study found a 4-fold increase of lymphoma in other sites (De Vita and
others 1998).

Clinical Manifestations

Numerous NHL tumor types associated with HCV infection have been
reported (Silvestri and others 1998), with follicular and lymphoplasmacytoid
lesions being the most common. Extranodal involvement is common (found in
65% of individuals with HCV), with liver and salivary glands being overrepresented (De Vita and others 1997; Zuckerman and others 1997). Individuals
with NHL present with symptoms related to enlargement of lymph nodes that
may be located throughout the lymphatic system. Visceral involvement with NHL
may remain occult for prolonged periods prior to diagnosis. A subset of
individuals will develop symptoms such as fever, night sweats, and weight loss
that may bring them to medical attention.
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Pathogenesis.

While it is clear that individuals with chronic HCV infection and hepatitis
leading to cirrhosis often develop hepatocellular carcinomas, the direct
oncogenic potential of HCV is controversial. Such a role cannot be completely
ruled out, since, e.g., HCV core protein has been reported to be involved in
transformation of cells to malignant phenotypes (Ray and others 1996). HCV
does show some lymphotrophic specificity but only in relatively small numbers of
peripheral blood mononuclear cells (PBMC) (Zignego and Brechot 1999), and
perhaps only under abnormal conditions such as immunosupression (Muratori
and others 1996; Laskus and others 2002) or cell transformation (Sung and
others 2003). The preponderance of data suggests that HCV-associated
lymphomas arise from abnormal B cell proliferation, with the mechanisms
outlined previously in this review.

Management.

As the potential of HCV to clonally expand B-lymphocytes and promote
lymphomagenesis has been further elucidated, there have been several small
trials examining the response of HCV-associated B-cell lymphoma to antiviral
therapy. Zuckerman et al. reported complete hematologic responses and
regression of B-cell clonality in thirteen of fifteen patients with chronic HCV
infection and t(14:18) translocation or IgH rearrangement, treated with either
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interferon-α or interferon-α and ribavirin for 6 to 12 months (Zuckerman and
others 2001). Vallisa et al. also reported complete or partial hematologic
responses in nine of twelve patients with HCV-associated, low grade B-cell
lymphoma treated with pegylated interferon-α and ribavirin for 6 to 12 months,
although molecular remission was not achieved as in the Zuckerman trial (Vallisa
and others 2005). Whether antiviral therapy for HCV-associated B-cell
lymphoma should supplant or be added to conventional chemotherapy, including
rituximab, is unclear as there have been no supporting clinical studies.

Membranoproliferative Glomerulonephritis (MPGN)

Disease.

MPGN is a disease that affects the glomeruli of the kidney. It is
characterized by endocapillary proliferation, monocytic infiltration, double contour
membranes, large eosinophilic, PAS-positive intraluminal deposits and vasculitis
of the small and medium sized renal arteries (Fornasieri and D'Amico 1996).
Electron microscopy indicates subendothelial deposits that may have structure
similarities to cryoglobulins (Cordonnier and others 1975). MPGN appears to
occur predominantly with type II cryoglobulins (Pucillo and Agnello 1994;
Fornasieri and D'Amico 1996). mRF appears to be a critical element in
deposition of cryoglobulins in the glomeruli (Fornasieri and D'Amico 1996) and
since HCV infection produces relatively high concentrations of mRF (Pucillo and
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Agnello 1994), this may be a reason for the predominance of HCV in
cryoglobulinemic glomerulonephritis.

Prevalence.

Reports linking HCV-related mixed cryoglobulinemia to MPGN find this
association in 33% (Agnello 2000) to 81% (Misiani and others 1992) of cases.
Data linking HCV infection as a whole to MPGN are more controversial. Reports
have been published supporting and opposing this premise. Neither argument is
convincing since studies to detect and characterize RF in MPGN lesions in the
absence of cryoglobulinemia and B cell clonal analysis that can detect mRF B
cells in the absence of cryoglobulinemia have not been performed.

Clinical Manifestations

The average patient with renal disease associated with HCV infection is
recognized when diagnosed with nephritic syndrome (71%). Most will have
serum albumin <3 g/dl with mild renal insufficiency (72%). Over time, a relatively
small number may progress to dialysis (Fornasieri and D'Amico 1996). Most of
these patients will have detectable cryoglobulins (59% initially – 85% overall) but
only 44% will present with extra-renal manifestations of cryoglobulinemia.
Clinical presentation of liver involvement is not a given. Up to 82% will show no
clinical manifestations of liver disease. However, up to 88% will have an

96

abnormal liver biopsy consistent with chronic HCV infection (Fornasieri and
D'Amico 1996). As in primary MC disease, complement levels will also be
depressed in most of these patients (Misiani and others 1992).

Pathogenesis

Renal biopsy will generally reveal endocapillary proliferation, monocytic
infiltration, and double contour membranes; all morphological features consistent
with immune complex disease. Detection of HCV RNA in the affected glomeruli
is inconsistent due to the high levels of RF-induced artifact. Notable is the fact
that RF from patients with type II MC shows a high affinity for cellular fibronectin,
which is highly concentrated in the glomerular mesangium. This has led to
speculation that RF induces deposition of Ig in the glomerulus irrespective of
HCV infection (Fornasieri and D'Amico 1996).

Management.

Antiviral therapy aimed at chronic HCV infection remains the most
effective treatment for HCV-associated MPGN, although recent studies using
rituximab are quite encouraging. Interferon-α and pegylated interferon-α both in
combination with ribavirin have been used successfully in this regard and have
been shown to halt the progression of renal failure in such patients (Giannico and
others 2000; Loustaud-Ratti and others 2002; Sabry and others 2002). While
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there is concern over the use of ribavirin in patients with renal insufficiency
whose threshold for hemolytic anemia is lowered, its combination with interferon
is advocated in these patients as long as its dose is titrated to account for a lower
creatinine clearance (Orlent and others 2005). As noted, very recent studies
suggest a role for rituximab in treating HCV-related glomerulonephritis
(Roccatello and others 2004; Garini and others 2005; Quartuccio and others
2006b).

Other Diseases

Evidence has been published linking a number of diseases to HCV
infection. In general, more research needs to be done to prove or disprove these
links. For example, HCV has been repeatedly linked to progressive declines in
pulmonary function in patients with underlying lung diseases such as asthma and
chronic obstructive pulmonary disease (COPD) (Kanazawa and others 2003;
Kanazawa and Yoshikawa 2004; Moorman and others 2005a). In patients who
already had a diagnosis of COPD, chronic HCV infection led to a more rapid
decline in forced expiratory volume (FEV1) and diffusing capacity for carbon
monoxide (DLCO), findings that were abrogated in those treated with interferon
(Kanazawa and others 2003). In a recent 6-year prospective trial, asthmatic
patients with chronic HCV who did not respond to interferon had greater impaired
reversibility to bronchodilators when compared to either HCV-negative controls or
to HCV-positive individuals who responded to interferon (Kanazawa and
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Yoshikawa 2004). Some data suggests that HCV infection may alter
acetylcholine-mediated airway tone (Kanazawa and Yoshikawa 2004). We have
shown that HCV core protein can alter IL-8 cytokine expression in pulmonary
fibroblasts, mediated by p38 MAPK (Moorman and others 2005b). Other smaller
studies also suggest a role for HCV infection in various pulmonary diseases,
including idiopathic pulmonary fibrosis (Manganelli and others 1996; Idilman and
others 2002).

Expert Commentary

While HCV infection has in the past been primarily considered a disease
of the liver, it is now clear that this systemic infection leads to serious health
issues beyond just the propensity to lead to chronic hepatitis and cirrhosis. The
majority of the diseases outlined in this review are at their core disorders of
immune signaling. HCV gene products such as envelope and core proteins and
NS5A appear to have significant effects on host immune responses, and these
may ultimately also facilitate the establishment of viral chronicity following acute
infection. The lack of latency with this particular virus supports the existence of
viral mechanisms by which host immune responses are either usurped or
avoided in an effort to establish chronicity.
For the majority of individuals who do go on to chronic HCV infection, the
consequences on the immune system appear to persist. While there are multiple
lines of evidence suggesting that HCV can be an immunosuppressive virus, the
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authors firmly believe that it is more accurate to state that HCV is
immundysregulatory. We and others have consistently found differential effects
on B and T lymphocyte function in the setting of both clinical disease and in in
vitro studies, with B cells exhibiting profiles consistent with activation and CD4+
and CD8+ T cells exhibiting altered or impaired cytokine and receptor
expressions, proliferation, and cell survival. The immune-associated disease
states that are observed in the setting of chronic HCV likely represent the results
of a complex interplay between these dysregulated immune responses (Figure
3.3).

Figure 3.3 Immunodysregulatory aspects of chronic HCV infection based on published studies.
CTL: Cytoxic T lymphocyte; IFN: interferon; IL: Interleukin; MAPK: Mitogen-activated protein kinase;
MHC: Major histocompatability complex; MPGN: Membraneoproliferative glomerulonephritis
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In contrast to HIV infection, characterized by a very dramatic loss of CD4+
T cells and extreme immunosuppression, chronic HCV infection leads to
dysregulated immune responses that are generally more subtle and certainly
more variable within a given infected individual. Not every infected patient will
develop mixed cryoglobulinemia, for example, but it would not be surprising to us
if the majority of HCV-infected patients exhibit altered B cell responses to some
degree when assayed in detail. We believe that translational studies focusing on
individuals with HCV-associated immune conditions will be the most fruitful
approach to determining how HCV and its gene products are altering the specific
arms of host immunity.
Unfortunately, much of the data regarding HCV-associated immune
dysfunction is derived from small populations and the data are often anecdotal.
The difficulty in accruing large numbers of affected individuals could be offset by
a multicenter approach to studying these diseases. Such an approach would be
excellent for facilitating clinical trials and translational studies and would better
define the specific immune-related issues that occur in the setting of HCV
infection.
In terms of therapy, there are a fair amount of clinical data suggesting that
combination therapy with interferon-α and ribavirin will ameliorate many of the
HCV-associated conditions to some extent, particularly in interferon responders.
In addition, it is of course desirable to completely eradicate this potentially
curable disease if at all possible to avoid not only immunodysregulatory diseases
but chronic hepatitis and all of its sequelae. All individuals with HCV infection
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should ideally be evaluated for treatment and offered combination therapy if
appropriate, although in practice this has not been the rule for a multitude of
reasons ranging from cost to toxicity of treatment to social barriers to care.
These patients need close clinical follow up, immunizations, and teaching
regarding lifestyle alterations including alcohol cessation. Treatment by either a
hepatologist or infectious diseases specialist is recommended because current
treatment options are quite toxic and require intense monitoring.
Therapy with rituximab is perhaps the most exciting modality that has
emerged for individuals with immunodysregulatory diseases associated with
HCV. Although still primarily anecdotal, the limited data do suggest that targeting
of B cells may be relatively effective for several of the conditions outlined herein.
The authors believe that individuals with HCV infection who are either not eligible
for or do not respond to combination interferon-α and ribavirin therapy, or who
have persistent immune disease despite therapy, should be considered for
treatment with rituximab and ideally should be enrolled in ongoing clinical trials
with this drug.

Five-year View

It is likely that within 5 years there will be much more clinical data
confirming the efficacy of drugs such as rituximab in treating HCV-associated
diseases. Anecdotal studies throughout the literature are quite encouraging for
this treatment, which targets B cells in particular and has comparatively few side
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effects. Clinical trials with rituximab are enrolling for the treatment of
cryoglobulinemic vasculitis, NHL, and Sjogren’s syndrome, but other HCVassociated conditions will assuredly be targeted and clinical data are
forthcoming.
Although treatment of the underlying HCV infection does lead to
improvement in some of these diseases, our current regimens of pegylated
interferon-α and ribavirin are fraught with side effects and cure less than half of
our infected patients, depending on their HCV genotype. A large number of new
treatments, however, are now in early phase clinical trials and promise improved
sustained virologic responses. These include novel protease, RNA polymerase,
and RNA helicase inhibitors. The ability to clear infection in the majority of
individuals may be a reality for clinicians in the very near future.

Key Issues

•

Hepatitis C virus (HCV) can dysregulate host immune responses through
interactions with host proteins and perturbation of signal transduction
cascades; this immunodysregulation may afford the virus the opportunity
to persist and to facilitate the development of immune disorders.

•

Mixed cryoglobulinemia is strongly associated with HCV, and renal
disease and lymphoma manifest at least some overlap with
cryoglobulinemia.

•

The interaction of the HCV gene products with key aspects of the host

103

immune system seems to be important in the pathophysiology of several
of the extrahepatic manifestations of HCV.
•

Antiviral therapy and/or treatment targeted at B cell populations are
efficacious for certain immune-related manifestations of HCV infection.
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CHAPTER 4

DISCUSSION

Despite the advances made in the area of HCV research we are still left
with many unanswered questions and few good options. There is no vaccine
available for HCV; there is no treatment that is consistently effective from patient
to patient and viral genotype to genotype; and finally, there is no conclusive
evidence that explains how HCV evades the human immune system and
establishes a chronic infection. In these studies we attempt to identify one
possible pathway that the virus may exploit to establish a chronic infection.
It has been established that extracellular hepatitis C core protein will bind
to the complement receptor gC1qR (Kittlesen and others 2000) and subsequently
suppress T-cell activity in vitro. This suppressive ability mimics C1q, which is the
natural ligand for gC1qR (Chen and others 1994), and can be blocked by the
addition of anti-gC1qR. Given that a strong T-cell response is necessary to
eliminate viral infections any perturbations of the T-cell response suggests a
possible mechanism for establishing a chronic viral infection.
Very recent data have shown that the expression of PD-1/PDL-1 to be
related to whether an acute viral challenge will be cleared by the host or develop
into a chronic infection. These data show that PD-1/PDL-1 is upregulated in a
chronic infection versus an acute infection and may play a role in T-cell anergy.
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Of most importance, these studies have shown that anergic T-cells can be
rescued by blocking the ligation of PDL-1 to PD-1.
We began these studies by determining the PD-1 expression levels on
PBMCs isolated from healthy donors versus PBMCs isolated from persons
chronically infected with HCV. Upon activation of these PBMCs by antiCD3/CD28 or no activation, we were able to demonstrate that in fact PD-1
expression is upregulated on PBMCs from the chronically infected donors when
compared to the healthy donors. We were further able to show that PD-1 is also
upregulated on the CD4+ and CD8+ subpopulations. We were also able to
demonstrate that the ligand for PD-1, PDL-1, is also upregulated on chronically
infected persons. Moreover, when isolated PBMCs were treated with other viral
proteins, such as HCV NS3, HIV Tat, and gp120, no change in PD-1 expression
was noted. Finally, to rule out the possibility that we had started with different
lymphocyte phenotype subpopulations, we compared the PD-1/PDL-1
expression levels of CD45RA and CD45RO on T-cells isolated from chronically
infected persons. In both a stimulated and unstimulated setting we show no
difference in the levels of PD-1/PDL-1 expression.
Our data suggest that PD-1/PDL-1 are upregulated in response to the
setting of a chronic HCV infection; how this occurs is unknown but seems likely
related to a hepatitis C viral product. Because previous data have shown that the
HCV core protein has suppressive effects on T-cells, we investigated whether
HCV core protein would have an effect on the expressed levels of PD-1 and
PDL-1. We demonstrated that HCV core will increase the expression of PD-1 in
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a dose dependent manner and that C1q will also increase the expression of PD-1
when compared to a control protein. This upregulation of expression, as induced
by HCV core, was also shown to be present on CD4+ and CD8+ T-cells.
Next, to determine if a the upregulation of PD-1 is mediated through HCV
core binding to gC1qR and to further support the link between core and PD-1
expression, we measured the levels of PD-1 mRNA in T-cells exposed to HCV
core. We found consistent upregulation of the message, beginning as early as 6
hours, after treatment with the core protein. We also employed anti-gC1qR in
these experiments and found that the antibody inhibited core’s ability to increase
the level of PD-1 message. To support the gC1qR findings we again measured
the expression level of PD-1, this time in healthy donor cells treated with core
alone, core plus a non-specific antibody, or core plus anti-gC1qR. Again, we
found that anti-gC1qR inhibited core’s ability to effect PD-1 changes, e.g. PD-1
upregulation.
Our last set of experiments were designed to determine if blocking the PD1/PDL-1 interaction in the presence of core protein would restore T-cell function.
We found that CD4+ and CD8+ cells in the presence of core protein show a
suppression of CD69 (a T-cell activation marker); yet, these same cells
demonstrated an increase of CD69 when treated with anti-PD-1 or anti-PDL-1.
We were also able to show that blocking with anti-PD1 or anti-PDL-1 will partially
restore T-cell proliferation (in the presence of core protein) and will decrease the
amount of apoptosis of T-cells (in the presence of core protein).
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HCV core is a known immunomodulatory viral antigen that circulates in the
plasma of infected individuals. Whether core is the cause or a cause of chronic
infection remains to be determined. Regardless of the role core is eventually
discovered to have, it seems clear that levels of PD-1 and PDL-1 do have a role
in establishing a chronic infection.
Data supporting the importance of PD-1 and its role in the immune
response are many; evidence suggests that PD-1/PDL-1 involvement is normal
for proper immune tolerance, autoimmune responses, and antitumor or antiviral
immune evasion (Nishimura and Honjo 2001; Dong and others 2002; Iwai and
others 2003; Chen 2004; Khoury and Sayegh 2004); the recent discovery that
PD-1 is upregulated on exhausted T-cells during a chronic viral infection in mice
(Barber and others 2006) and their subsequent reactivation by blocking the
interaction between PD-1 and PDL-1. Interestingly, this exhaustion of host Tcells as a means of immune evasion may also be a mechanism employed by
other persistent viruses in humans, such as HIV (Day and others 2006; Freeman
and others 2006; Petrovas and others 2006; Trautmann and others 2006a). The
data so far make a strong suggestion for the importance of PD-1 in general and
its potential role in the establishment of viral chronicity. If this is indeed the case
then either blocking the PD-1/PDL-1 interaction or blocking the HCV core
protein/gC1qR interaction would offer potential new treatment options for
management of hepatitis C.
Our lab has also recently shown that suppressor of cytokine signaling-1
(SOCS-1) is also upregulated in T-cells in the presence of HCV core. SOCS-1,
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like PD-1, is a negative regulator of T-cells. With this knowledge that two known
negative regulators of T-cells are upregulated by HCV core protein the next step
will be to examine the role of PD-1 and SOCS-1 in regulating T-cell signaling
during HCV infection as described in Figure 4.1.

A)

TCR

HCV core

x

B)

gC1qR

PD-1

?
IFN-γ
signaling

SOCS-1

gC1qR

PD-1

?
IFN-γ
signaling

HCV core

TCR

x

SOCS-1

Figure 4.1 Schematic representation of experiments designed to delineate signaling by negative
modulators PD-1 (A) or SOCS-1 (B) during HCV core/gC1qR-mediated T cell inhibition.

124

CHAPTER 5

ADDITIONAL INFORMATION

In addition to the data presented and discussed in chapters one through
three, we also attempted to further characterize the hepatitis C core protein. Our
hypothesis was that HCV core protein inhibited specific T-cell signaling pathways
mediated by its ability to bind to gC1qR and this inhibition subsequently inhibited
the T-cell response. Our overall strategy was to create and express mutations of
the HCV core protein and compare the mutated core effects on T-cell responses
to the wild type core effects on T-cell responses.
We employed a scanning alanine mutagenesis technique to generate the
core mutants. We were able to create 10 mutations (as confirmed by
sequencing) in the area of HCV core deemed most likely to contain the binding
site to gC1qR. We were then able to clone these mutants into an E. coli
expression system that would express the now mutant proteins with a 6 histidine
tag. We then attempted expression and were able to express the mutant
proteins and confirm the expression via western blot and coomassie gel. We
were also able to purify the proteins by using Ni+ columns. We were less
successful in our attempts to concentrate the protein. Concentration attempts
seemed to cause the core protein to ‘disappear’ as we could see no signal on
post-concentration analysis. Efforts to block the concentration system using
unrelated proteins had no positive effect.
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We then compared T-cell responses using proteins that we were able to
express and found no differences. Whether this was due to small concentrations
of the mutant proteins or other reasons is unknown. We ultimately abandoned
this avenue of research but feel that with adequate funding and time that needed
progress could be accomplished in this area.
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